1
|
Friedmacher F, Rolle U. Interstitial cells of Cajal: clinical relevance in pediatric gastrointestinal motility disorders. Pediatr Surg Int 2023; 39:188. [PMID: 37101012 PMCID: PMC10133055 DOI: 10.1007/s00383-023-05467-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 04/03/2023] [Indexed: 04/28/2023]
Abstract
Interstitial cells of Cajal (ICCs) are pacemaker cells of gastrointestinal motility that generate and transmit electrical slow waves to smooth muscle cells in the gut wall, thus inducing phasic contractions and coordinated peristalsis. Traditionally, tyrosine-protein kinase Kit (c-kit), also known as CD117 or mast/stem cell growth factor receptor, has been used as the primary marker of ICCs in pathology specimens. More recently, the Ca2+-activated chloride channel, anoctamin-1, has been introduced as a more specific marker of ICCs. Over the years, various gastrointestinal motility disorders have been described in infants and young children in which symptoms of functional bowel obstruction arise from ICC-related neuromuscular dysfunction of the colon and rectum. The current article provides a comprehensive overview of the embryonic origin, distribution, and functions of ICCs, while also illustrating the absence or deficiency of ICCs in pediatric patients with Hirschsprung disease intestinal neuronal dysplasia, isolated hypoganglionosis, internal anal sphincter achalasia, and congenital smooth muscle cell disorders such as megacystis microcolon intestinal hypoperistalsis syndrome.
Collapse
Affiliation(s)
- Florian Friedmacher
- Department of Paediatric Surgery and Paediatric Urology, University Hospital Frankfurt, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany
| | - Udo Rolle
- Department of Paediatric Surgery and Paediatric Urology, University Hospital Frankfurt, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany.
| |
Collapse
|
2
|
Song MH, Park JW, Kim MJ, Shin YK, Kim SC, Jeong SY, Ku JL. Colon cancer organoids using monoclonal organoids established in four different lesions of one cancer patient reveal tumor heterogeneity and different real-time responsiveness to anti-cancer drugs. Biomed Pharmacother 2022; 152:113260. [PMID: 35691158 DOI: 10.1016/j.biopha.2022.113260] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2022] [Revised: 05/30/2022] [Accepted: 06/06/2022] [Indexed: 11/02/2022] Open
Abstract
Organoid culture technique has been taking center stage as a next-generation ex-vivo model due to advancement of stem cell research techniques. The importance of the laboratory-based ex vivo model has increasingly been recognized for recapitulating histological, and physioglocal conditions of in vivo microenviorment. Accordingly, the use of this technique has also broadened the understanding of intratumoral heterogeneity which is closely associated with varied drug responses observed in patients. Likewise, studies on heterogeneity within a single tumor tissue have drawn much attention. Here, we isolated 15 single clones from 4 tumor organoid lines from 1 patient at a primary passage from one patient. Each organoid line showed variable alterations in both genotype and phenotype. Furthermore, our methodological approach on drug test employing a high-throughput screening system enabled us to pinpoint the optimal time frame for anti-cancer drugs within a single tumor. We propose that our method can effectively reveal the heterogeneity of time-point in drug response, and the most optimal therapeutic strategies for individual patient.
Collapse
Affiliation(s)
- Myoung-Hyun Song
- Korean Cell Line Bank, Laboratory of Cell Biology, Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080, South Korea; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul 03080, South Korea; Cancer Research Institute, Seoul National University, Seoul 03080, South Korea
| | - Ji Won Park
- Cancer Research Institute, Seoul National University, Seoul 03080, South Korea; Department of Surgery, Seoul National University College of Medicine, Seoul 03080, South Korea
| | - Min Jung Kim
- Cancer Research Institute, Seoul National University, Seoul 03080, South Korea; Department of Surgery, Seoul National University College of Medicine, Seoul 03080, South Korea
| | - Young-Kyoung Shin
- Korean Cell Line Bank, Laboratory of Cell Biology, Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080, South Korea
| | - Soon-Chan Kim
- Korean Cell Line Bank, Laboratory of Cell Biology, Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080, South Korea; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul 03080, South Korea; Cancer Research Institute, Seoul National University, Seoul 03080, South Korea; Ischemic/Hypoxic Disease Institute, Seoul National University College of Medicine, Seoul 03080, South Korea
| | - Seung-Yong Jeong
- Cancer Research Institute, Seoul National University, Seoul 03080, South Korea; Department of Surgery, Seoul National University College of Medicine, Seoul 03080, South Korea; Seoul National University Boramae Medical Center, Seoul 07061, South Korea.
| | - Ja-Lok Ku
- Korean Cell Line Bank, Laboratory of Cell Biology, Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080, South Korea; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul 03080, South Korea; Cancer Research Institute, Seoul National University, Seoul 03080, South Korea; Ischemic/Hypoxic Disease Institute, Seoul National University College of Medicine, Seoul 03080, South Korea.
| |
Collapse
|
3
|
Ueshima C, Kataoka TR, Osakabe M, Sugimoto A, Ushirokawa A, Shibata Y, Nakamura H, Shibuya R, Minamiguchi S, Sugai T, Haga H. Decidualization of Stromal Cells Promotes Involvement of Mast Cells in Successful Human Pregnancy by Increasing Stem Cell Factor Expression. Front Immunol 2022; 13:779574. [PMID: 35173715 PMCID: PMC8841734 DOI: 10.3389/fimmu.2022.779574] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2021] [Accepted: 01/17/2022] [Indexed: 11/13/2022] Open
Abstract
Decidualization of endometrial stromal cells and the presence of immunocompetent cells, including human mast cells, play important roles in the establishment of pregnancy. In the present study, the effects of decidualization of endometrial stromal cells on the function of decidual mast cells were elucidated. The in vitro assay revealed that decidualization of an endometrial stromal cell line, T HESCs, increased stem cell factor (SCF) mRNA expression. Decidualization of T HESCs enhanced the production of leukemia inhibitory factor (LIF), and the migration of LAD2 cells when co-cultured with T HESCs and LAD2 cells. In addition, decidualization of T HESCs enhanced cell migration in a human trophoblast cell line, HTR-8/SVneo, increased CD9 expression, a marker for extravillous trophoblast (EVT) differentiation, and decreased the secretion of β human chorionic gonadotropin (hCG), a marker for syncytiotrophoblast (ST) differentiation, when co-cultured with T HESCs, LAD2 cells, and HTR-8/SVneo cells, in a LIF-dependent manner. Histological samples from uterine pregnancies, including decidual stromal cells, showed increased SCF mRNA expression, mast cell numbers and LIF mRNA expression thereof compared with tubal pregnancy. SCF produced by decidual stromal cells enhanced the migration and LIF production of mast cells, and promoted the migration and differentiation of trophoblasts to increase the likelihood of successful human pregnancy.
Collapse
Affiliation(s)
- Chiyuki Ueshima
- Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan
| | - Tatsuki R. Kataoka
- Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan
- Department of Pathology, Iwate Medical University, Yahaba-cho, Japan
- *Correspondence: Tatsuki R. Kataoka, ;
| | - Mitsumasa Osakabe
- Department of Molecular Diagnostic Pathology, Iwate Medical University, Yahaba-cho, Japan
| | - Akihiko Sugimoto
- Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan
| | | | - Yuji Shibata
- Department of Pathology, Iwate Medical University, Yahaba-cho, Japan
- Department of Molecular Diagnostic Pathology, Iwate Medical University, Yahaba-cho, Japan
| | - Hiroya Nakamura
- Department of Pathology, Iwate Medical University, Yahaba-cho, Japan
| | - Rintaro Shibuya
- Department of Dermatology, Kyoto University Hospital, Kyoto, Japan
| | | | - Tamotsu Sugai
- Department of Molecular Diagnostic Pathology, Iwate Medical University, Yahaba-cho, Japan
| | - Hironori Haga
- Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan
| |
Collapse
|
4
|
PI3K/PTEN/AKT Signaling Pathways in Germ Cell Development and Their Involvement in Germ Cell Tumors and Ovarian Dysfunctions. Int J Mol Sci 2021; 22:ijms22189838. [PMID: 34575999 PMCID: PMC8467417 DOI: 10.3390/ijms22189838] [Citation(s) in RCA: 25] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2021] [Revised: 09/07/2021] [Accepted: 09/09/2021] [Indexed: 11/24/2022] Open
Abstract
Several studies indicate that the PI3K/PTEN/AKT signaling pathways are critical regulators of ovarian function including the formation of the germ cell precursors, termed primordial germ cells, and the follicular pool maintenance. This article reviews the current state of knowledge of the functional role of the PI3K/PTEN/AKT pathways during primordial germ cell development and the dynamics of the ovarian primordial follicle reserve and how dysregulation of these signaling pathways may contribute to the development of some types of germ cell tumors and ovarian dysfunctions.
Collapse
|
5
|
Basak M, Mitra S, Agnihotri SK, Jain A, Vyas A, Bhatt MLB, Sachan R, Sachdev M, Nemade HB, Bandyopadhyay D. Noninvasive Point-of-Care Nanobiosensing of Cervical Cancer as an Auxiliary to Pap-Smear Test. ACS APPLIED BIO MATERIALS 2021; 4:5378-5390. [PMID: 35007017 DOI: 10.1021/acsabm.1c00470] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
A potential cancer antigen (Ag), protein-phosphatase-1-gamma-2 (PP1γ2), with a restricted expression in testis and sperms has been identified as a biomarker specific to cervical cancer (CaCx). Detection of this cancer biomarker antigen (NCB-Ag) in human urine opens up the possibility of noninvasive detection of CaCx to supplement the dreaded and invasive Pap-smear test. A colorimetric response of an assembly of gold nanoparticles (Au NPs) has been employed for the quantitative, noninvasive, and point-of-care-testing of CaCx in the urine. In order to fabricate the immunosensor, Au NPs of sizes ∼5-20 nm have been chemically modified with a linker, 3,3'-di-thio-di-propionic-acid-di(n-hydroxy-succinimide-ester) (DTSP) to attach the antibody (Ab) specific to the NCB-Ag. Interestingly, the addition of Ag to the composite of Ab-DTSP-Au NPs leads to a significant hypsochromic shift due to a localized surface plasmon resonance phenomenon, which originates from the specific epitope-paratope interaction between the NCB-Ag and Ab-DTSP-Au NPs. The variations in the absorbance and wavelength shift during such attachments of different concentrations of NCB-Ag on the Ab-DTSP-Au NPs composite have been employed as a calibration to identify NCB-Ag in human urine. An in-house prototype has been assembled by integrating a light-emitting diode of a narrow range wavelength in one side of a cuvette in which the reaction has been performed while a sensitive photodetector to the other side to transduce the transmitted signal associated with the loading of NCB-Ag in the Ab-DTSP-Au NPs composite. The proposed immunosensing platform has been tested against other standard proteins to ensure noninterference alongside proving the proof-for-specificity of the NCB detection.
Collapse
Affiliation(s)
- Mitali Basak
- Centre for Nanotechnology, Indian Institute of Technology Guwahati, Guwahati, Assam 781039, India
| | - Shirsendu Mitra
- Department of Chemical Engineering, Indian Institute of Technology Guwahati, Guwahati, Assam 781039, India
| | - Saurabh Kumar Agnihotri
- Endocrinology, Division, CSIR-Central Drug Research Institute Lucknow, Lucknow, Uttar Pradesh 226 031, India
| | - Ankita Jain
- Endocrinology, Division, CSIR-Central Drug Research Institute Lucknow, Lucknow, Uttar Pradesh 226 031, India
| | - Akanksha Vyas
- Endocrinology, Division, CSIR-Central Drug Research Institute Lucknow, Lucknow, Uttar Pradesh 226 031, India
| | | | - Rekha Sachan
- King George's Medical University, Lucknow, Uttar Pradesh 226 003, India
| | - Monika Sachdev
- Endocrinology, Division, CSIR-Central Drug Research Institute Lucknow, Lucknow, Uttar Pradesh 226 031, India
| | - Harshal B Nemade
- Centre for Nanotechnology, Indian Institute of Technology Guwahati, Guwahati, Assam 781039, India
| | - Dipankar Bandyopadhyay
- Centre for Nanotechnology, Indian Institute of Technology Guwahati, Guwahati, Assam 781039, India.,Department of Chemical Engineering, Indian Institute of Technology Guwahati, Guwahati, Assam 781039, India
| |
Collapse
|
6
|
Ghezelayagh Z, Abtahi NS, Rezazadeh Valojerdi M, Mehdizadeh A, Ebrahimi B. The combination of basic fibroblast growth factor and kit ligand promotes the proliferation, activity and steroidogenesis of granulosa cells during human ovarian cortical culture. Cryobiology 2020; 96:30-36. [PMID: 32871128 DOI: 10.1016/j.cryobiol.2020.08.011] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2020] [Revised: 08/04/2020] [Accepted: 08/26/2020] [Indexed: 12/22/2022]
Abstract
Different factors, such as basic fibroblast growth factor (bFGF) and kit ligand (KL), are used in ovarian cortical culture to promote activation of primordial follicles. In the present study, the effects of bFGF and KL, alone and in combination, were evaluated on human follicular activation and growth during in-situ cortical culture. Slow frozen-thawed human ovarian cortical tissues (n = 6) were cultured in 4 different groups: 1) control (base medium), 2) KL (base medium; BM + 100 ng/ml KL), 3) bFGF (BM + 100 ng/ml bFGF) and 4) bFGF + KL (BM + 100 ng/ml KL + 100 ng/ml bFGF) for a week. The proportion of morphologically normal and degenerated follicles at different developmental stages, secreted hormonal levels and specific gene expressions were compared. Although the proportion of growing follicles was higher than primordial counterpart in all cultured groups, no significant differences were observed among the cultured groups. In all cultured groups, anti-Müllerian hormone (AMH), progesterone and estradiol hormones levels increased after 7 days of culture; however, this increase was only significant for estradiol in the bFGF + KL group. The expression of Ki67 gene indicated an increase in ovarian cell proliferation in the three experimental groups compared to the control group, however this increment was only significant for the bFGF + KL group. It can be concluded that KL and bFGF factors individually have no beneficial effects on in-situ follicular growth, but their combination positively influences steroidogenesis of granulosa cells without significantly increasing the number of growing follicles.
Collapse
Affiliation(s)
- Zeinab Ghezelayagh
- Department of Developmental Biology, University of Science and Culture, ACECR, Tehran, Iran; Department of Embryology, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran
| | - Naeimeh Sadat Abtahi
- Department of Embryology, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran
| | - Mojtaba Rezazadeh Valojerdi
- Department of Embryology, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran; Department of Anatomy, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
| | - Aboulfazl Mehdizadeh
- Endometriosis Research Center, Iran University of Medical Sciences, Tehran, Iran
| | - Bita Ebrahimi
- Department of Embryology, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran.
| |
Collapse
|
7
|
Alam MH, Miyano T. Interaction between growing oocytes and granulosa cells in vitro. Reprod Med Biol 2020; 19:13-23. [PMID: 31956281 PMCID: PMC6955591 DOI: 10.1002/rmb2.12292] [Citation(s) in RCA: 94] [Impact Index Per Article: 23.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2019] [Revised: 07/22/2019] [Accepted: 07/25/2019] [Indexed: 01/21/2023] Open
Abstract
BACKGROUND Oocyte growth is accompanied by follicular development in mammalian ovaries. Since the discovery of two oocyte-derived factors, growth differentiation factor 9 (GDF9), and bone morphogenetic protein 15 (BMP15), knowledge of the bidirectional communication between oocytes and granulosa cells for ovarian function and fertility has been accumulated. In addition, the growth culture system of oocytes has been improved, further promoting the studies on the communication between oocytes and granulosa cells in vitro. METHODS We provide an overview of the role of granulosa cells in oocyte growth and the role of oocytes in follicular development along with our recent findings in culture experiments of bovine growing oocytes. MAIN FINDINGS Granulosa cells supply nutrients and metabolites through gap junctions to oocytes and secrete paracrine signals to regulate oocytes. Oocytes regulate granulosa cell proliferation and differentiation and induce antrum formation via GDF9 and BMP15. CONCLUSION Oocytes actively participate in various aspects of follicular development, including antrum formation via the oocyte-derived factors GDF9 and BMP15, whose synthesis is probably regulated by granulosa cells. In vitro studies will reveal the precise communication loop between oocytes and granulosa cells that facilitates the coordinated development of oocytes and granulosa cells in the follicles.
Collapse
Affiliation(s)
- Md Hasanur Alam
- Department of Animal Science, Faculty of Animal HusbandryBangladesh Agricultural UniversityMymensinghBangladesh
- Graduate School of Agricultural ScienceKobe UniversityKobeJapan
| | - Takashi Miyano
- Graduate School of Agricultural ScienceKobe UniversityKobeJapan
| |
Collapse
|
8
|
Park M, Kim HR, Kim YS, Yang SC, Yoon JA, Lyu SW, Lim HJ, Hong SH, Song H. Estrogen-induced transcription factor EGR1 regulates c-Kit transcription in the mouse uterus to maintain uterine receptivity for embryo implantation. Mol Cell Endocrinol 2018; 470:75-83. [PMID: 28965972 DOI: 10.1016/j.mce.2017.09.033] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/03/2017] [Revised: 09/22/2017] [Accepted: 09/27/2017] [Indexed: 01/14/2023]
Abstract
Early growth response 1 (Egr1) is a key transcription factor that mediates the action of estrogen (E2) to establish uterine receptivity for embryo implantation. However, few direct target genes of EGR1 have been identified in the uterus. Here, we demonstrated that E2 induced EGR1-regulated transcription of c-Kit, which plays a crucial role in cell fate decisions. Spatiotemporal expression of c-Kit followed that of EGR1 in uteri of ovariectomized mice at various time points after E2 treatment. E2 activated ERK1/2 and p38 to induce EGR1, which then activated c-Kit expression in the uterus. EGR1 transfection produced rapid and transient induction of c-KIT in a time- and dose-dependent manner. Furthermore, luciferase assays to measure c-Kit promoter activity confirmed that a functional EGR1 binding site(s) (EBS) was located within -1 kb of the c-Kit promoter. Site-directed mutagenesis and chromatin immunoprecipitation-PCR for three putative EBS within -1 kb demonstrated that the EBS at -818/-805 was critical for EGR1-dependent c-Kit transcription. c-Kit expression was significantly increased in the uterus on day 4 and administration of Masitinib, a c-Kit inhibitor, effectively interfered with embryo implantation. Collectively, our results showed that estrogen induces transcription factor EGR1 to regulate c-Kit transcription for uterine receptivity for embryo implantation in the mouse uterus.
Collapse
Affiliation(s)
- Mira Park
- Department of Biomedical Science, CHA University, Seongnam, Republic of Korea
| | - Hye-Ryun Kim
- Department of Biomedical Science, CHA University, Seongnam, Republic of Korea
| | - Yeon Sun Kim
- Department of Biomedical Science, CHA University, Seongnam, Republic of Korea
| | - Seung Chel Yang
- Department of Biomedical Science, CHA University, Seongnam, Republic of Korea
| | - Jung Ah Yoon
- Fertility Center of Gangnam Medical Center, CHA University, Seoul, Republic of Korea
| | - Sang Woo Lyu
- Fertility Center of Gangnam Medical Center, CHA University, Seoul, Republic of Korea
| | - Hyunjung Jade Lim
- Department of Veterinary Medicine, Konkuk University, Seoul, Republic of Korea
| | - Seok-Ho Hong
- Department of Internal Medicine, Kangwon National University, Chuncheon, Kangwon, Republic of Korea.
| | - Haengseok Song
- Department of Biomedical Science, CHA University, Seongnam, Republic of Korea.
| |
Collapse
|
9
|
Ueshima C, Kataoka TR, Hirata M, Sugimoto A, Iemura Y, Minamiguchi S, Nomura T, Haga H. Possible Involvement of Human Mast Cells in the Establishment of Pregnancy via Killer Cell Ig-Like Receptor 2DL4. THE AMERICAN JOURNAL OF PATHOLOGY 2018; 188:1497-1508. [PMID: 29577936 DOI: 10.1016/j.ajpath.2018.02.012] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/15/2017] [Revised: 01/30/2018] [Accepted: 02/22/2018] [Indexed: 12/21/2022]
Abstract
The involvement of mast cells in the establishment of pregnancy is unclear. Herein, we found that human mast cells are present in the decidual tissues of parous women and expressed a human-specific protein killer cell Ig-like receptor (KIR) 2DL4, a receptor for human leukocyte antigen G expressed on human trophoblasts. In contrast, decreased numbers of decidual mast cells and reduced KIR2DL4 expression were observed in these cells of infertile women who had undergone long-term corticosteroid treatment. Co-culture of the human mast cell line, LAD2, and human trophoblast cell line, HTR-8/SVneo, accelerated the migration and tube formation of HTR-8/SVneo cells in a KIR2DL4-dependent manner. These observations suggest the possible involvement of human mast cells in the establishment of pregnancy via KIR2DL4 and that long-term corticosteroid treatment may cause infertility by influencing the phenotypes of decidual mast cells.
Collapse
Affiliation(s)
- Chiyuki Ueshima
- Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan
| | - Tatsuki R Kataoka
- Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan.
| | - Masahiro Hirata
- Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan
| | - Akihiko Sugimoto
- Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan
| | - Yoshiki Iemura
- Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan
| | | | - Takashi Nomura
- Department of Dermatology, Kyoto University Hospital, Kyoto, Japan
| | - Hironori Haga
- Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan
| |
Collapse
|
10
|
Figueira MI, Cardoso HJ, Correia S, Maia CJ, Socorro S. The stem cell factor (SCF)/c-KIT system in carcinogenesis of reproductive tissues: What does the hormonal regulation tell us? Cancer Lett 2017; 405:10-21. [DOI: 10.1016/j.canlet.2017.07.017] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2017] [Revised: 07/15/2017] [Accepted: 07/17/2017] [Indexed: 12/13/2022]
|
11
|
Elzinga-Tinke JE, Dohle GR, Looijenga LH. Etiology and early pathogenesis of malignant testicular germ cell tumors: towards possibilities for preinvasive diagnosis. Asian J Androl 2016; 17:381-93. [PMID: 25791729 PMCID: PMC4430936 DOI: 10.4103/1008-682x.148079] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Malignant testicular germ cell tumors (TGCT) are the most frequent cancers in Caucasian males (20-40 years) with an 70% increasing incidence the last 20 years, probably due to combined action of (epi)genetic and (micro)environmental factors. It is expected that TGCT have carcinoma in situ(CIS) as their common precursor, originating from an embryonic germ cell blocked in its maturation process. The overall cure rate of TGCT is more than 90%, however, men surviving TGCT can present long-term side effects of systemic cancer treatment. In contrast, men diagnosed and treated for CIS only continue to live without these long-term side effects. Therefore, early detection of CIS has great health benefits, which will require an informative screening method. This review described the etiology and early pathogenesis of TGCT, as well as the possibilities of early detection and future potential of screening men at risk for TGCT. For screening, a well-defined risk profile based on both genetic and environmental risk factors is needed. Since 2009, several genome wide association studies (GWAS) have been published, reporting on single-nucleotide polymorphisms (SNPs) with significant associations in or near the genes KITLG, SPRY4, BAK1, DMRT1, TERT, ATF7IP, HPGDS, MAD1L1, RFWD3, TEX14, and PPM1E, likely to be related to TGCT development. Prenatal, perinatal, and postnatal environmental factors also influence the onset of CIS. A noninvasive early detection method for CIS would be highly beneficial in a clinical setting, for which specific miRNA detection in semen seems to be very promising. Further research is needed to develop a well-defined TGCT risk profile, based on gene-environment interactions, combined with noninvasive detection method for CIS.
Collapse
Affiliation(s)
| | | | - Leendert Hj Looijenga
- Department of Pathology, Laboratory of Experimental Patho-Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands
| |
Collapse
|
12
|
Tu X, Kuang Z, Gong X, Shi Y, Yu L, Shi H, Wang J, Sun Z. The Influence of LepR Tyrosine Site Mutations on Mouse Ovary Development and Related Gene Expression Changes. PLoS One 2015; 10:e0141800. [PMID: 26529315 PMCID: PMC4631549 DOI: 10.1371/journal.pone.0141800] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2015] [Accepted: 10/13/2015] [Indexed: 11/30/2022] Open
Abstract
Leptin exerts many biological functions, such as in metabolism and reproduction, through binding to and activating the leptin receptor, LepRb, which is expressed in many regions of the brain. To better understand the roles of LepR downstream signaling pathways, Y123F mice, which expressed mutant leptin receptors with phenylalanine (F) substituted for three tyrosines (Y) (Tyr985, Tyr1077 and Tyr1138), were generated. The body weight and abdominal fat deposits of Y123F homozygous mice (HOM) were higher than those of wild-type mice (WT). HOM ovaries were atrophic and the follicles developed abnormally; however, the HOM ovaries did not exhibit polycystic phenotypes. Moreover, Y123F HOM adults had no estrous cycle and the blood estrogen concentration remained stable at a low level below detection limit of 5 pg/ml. LepR expression in HOM ovaries was higher than in WT ovaries. Using cDNA Microarrays, the mRNA expressions of 41 genes were increased, and 100 were decreased in HOM vs. WT ovaries, and many signaling pathways were evaluated to be involved significantly. The expressions of 19 genes were validated by real-time quantitative PCR, most of which were consistent with the microarray results. Thus, Y123F HOM mice were suggested as a new animal model of PCOS for research that mainly emphasizes metabolic disorders and anovulation, but not the polycystic phenotype. Meanwhile, using the model, we found that JAK-STAT and hormone biosynthesis pathways were involved in the follicular development and ovulation disorders caused by LepR deficiency in ovaries, although we could not exclude indirect actions from the brain.
Collapse
Affiliation(s)
- Xiaoyu Tu
- Shanghai Medical College, Institute of Reproduction and Development, Fudan University, Shanghai, P. R. China
| | - Zhichao Kuang
- Shanghai Medical College, Institute of Reproduction and Development, Fudan University, Shanghai, P. R. China
| | - Xia Gong
- Department of Food Science, Shanghai Business School, Shanghai, P. R. China
| | - Yan Shi
- Key Laboratory of Contraceptive Drugs and Devices of National Population and Family Planning Commission of China, Shanghai Institute of Planned Parenthood Research, Shanghai, P. R. China
| | - Lin Yu
- Key Laboratory of Contraceptive Drugs and Devices of National Population and Family Planning Commission of China, Shanghai Institute of Planned Parenthood Research, Shanghai, P. R. China
| | - Huijuan Shi
- Key Laboratory of Contraceptive Drugs and Devices of National Population and Family Planning Commission of China, Shanghai Institute of Planned Parenthood Research, Shanghai, P. R. China
| | - Jian Wang
- Key Laboratory of Contraceptive Drugs and Devices of National Population and Family Planning Commission of China, Shanghai Institute of Planned Parenthood Research, Shanghai, P. R. China
| | - Zhaogui Sun
- Key Laboratory of Contraceptive Drugs and Devices of National Population and Family Planning Commission of China, Shanghai Institute of Planned Parenthood Research, Shanghai, P. R. China
- * E-mail:
| |
Collapse
|
13
|
Joensuu H, Eriksson M, Sundby Hall K, Reichardt A, Hartmann JT, Pink D, Ramadori G, Hohenberger P, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Nilsson B, Sihto H, Bono P, Kallio R, Junnila J, Alvegård T, Reichardt P. Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial. J Clin Oncol 2015; 34:244-50. [PMID: 26527782 DOI: 10.1200/jco.2015.62.9170] [Citation(s) in RCA: 135] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
PURPOSE Three years of adjuvant imatinib therapy are recommended for patients with GI stromal tumor (GIST) with high-risk features, according to survival findings in the Scandinavian Sarcoma Group XVIII/AIO (Arbeitsgemeinschaft Internistische Onkologie) trial. To investigate whether the survival benefits have persisted, we performed the second planned analysis of the trial. PATIENTS AND METHODS Eligible patients had macroscopically completely excised, KIT-positive GIST with a high risk of recurrence, as determined by using the modified National Institutes of Health criteria. After surgery, the patients were randomly assigned to receive imatinib for either 1 or 3 years. The primary objective was recurrence-free survival (RFS), and the secondary objectives included survival. RESULTS A total of 400 patients were entered onto this open-label study between February 4, 2004, and September 29, 2008. During a median follow-up of 90 months, 171 recurrences and 69 deaths were detected. Patients assigned to the 3-year group had longer RFS than those assigned to the 1- year group; 5-year RFS was 71.1% versus 52.3%, respectively (hazard ratio [HR], 0.60; 95% CI 0.44 to 0.81; P < .001), and survival was 91.9% versus 85.3% (HR, 0.60; 95% CI, 0.37 to 0.97; P = .036). Patients in the 3-year group survived longer in the subset with centrally confirmed GIST and without macroscopic metastases at study entry (93.4% v 86.8%; HR, 0.53; 95% CI, 0.30 to 0.93; P = .024). Similar numbers of cardiac events and second cancers were recorded in the groups. CONCLUSION Three years of adjuvant imatinib therapy results in longer survival than 1 year of imatinib. High 5-year survival rates are achievable in patient populations with high-risk GIST.
Collapse
Affiliation(s)
- Heikki Joensuu
- Heikki Joensuu and Petri Bono, Comprehensive Cancer Center Helsinki; Heikki Joensuu, Harri Sihto, and Petri Bono, University of Helsinki, Helsinki; Raija Kallio, Oulu University Hospital, Oulu; Jouni Junnila, 4Pharma, Turku, Finland; Mikael Eriksson and Thor Alvegård, Lund University, Lund; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Kirsten Sundby Hall, Oslo University Hospital, Oslo, Norway; Annette Reichardt, Daniel Pink, and Peter Reichardt, Sarkomzentrum Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Berlin; Jörg T. Hartmann, Franziskus Hospital, Catholic Hospital Consortium Ostwestfalen, Bielefeld; Giuliano Ramadori, University of Göttingen, Göttingen; Peter Hohenberger, Mannheim University Medical Center, Mannheim; Salah-Eddin Al-Batran, Klinik für Onkologie und Hämatologie am Krankenhaus Nordwest, Frankfurt; Marcus Schlemmer, University Hospital Großhadern, Ludwig Maximilians University, Munich; Sebastian Bauer, Sarcoma Center, West German Cancer Center, Essen; and Eva Wardelmann, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany. heikki.joensuu@hus
| | - Mikael Eriksson
- Heikki Joensuu and Petri Bono, Comprehensive Cancer Center Helsinki; Heikki Joensuu, Harri Sihto, and Petri Bono, University of Helsinki, Helsinki; Raija Kallio, Oulu University Hospital, Oulu; Jouni Junnila, 4Pharma, Turku, Finland; Mikael Eriksson and Thor Alvegård, Lund University, Lund; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Kirsten Sundby Hall, Oslo University Hospital, Oslo, Norway; Annette Reichardt, Daniel Pink, and Peter Reichardt, Sarkomzentrum Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Berlin; Jörg T. Hartmann, Franziskus Hospital, Catholic Hospital Consortium Ostwestfalen, Bielefeld; Giuliano Ramadori, University of Göttingen, Göttingen; Peter Hohenberger, Mannheim University Medical Center, Mannheim; Salah-Eddin Al-Batran, Klinik für Onkologie und Hämatologie am Krankenhaus Nordwest, Frankfurt; Marcus Schlemmer, University Hospital Großhadern, Ludwig Maximilians University, Munich; Sebastian Bauer, Sarcoma Center, West German Cancer Center, Essen; and Eva Wardelmann, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany
| | - Kirsten Sundby Hall
- Heikki Joensuu and Petri Bono, Comprehensive Cancer Center Helsinki; Heikki Joensuu, Harri Sihto, and Petri Bono, University of Helsinki, Helsinki; Raija Kallio, Oulu University Hospital, Oulu; Jouni Junnila, 4Pharma, Turku, Finland; Mikael Eriksson and Thor Alvegård, Lund University, Lund; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Kirsten Sundby Hall, Oslo University Hospital, Oslo, Norway; Annette Reichardt, Daniel Pink, and Peter Reichardt, Sarkomzentrum Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Berlin; Jörg T. Hartmann, Franziskus Hospital, Catholic Hospital Consortium Ostwestfalen, Bielefeld; Giuliano Ramadori, University of Göttingen, Göttingen; Peter Hohenberger, Mannheim University Medical Center, Mannheim; Salah-Eddin Al-Batran, Klinik für Onkologie und Hämatologie am Krankenhaus Nordwest, Frankfurt; Marcus Schlemmer, University Hospital Großhadern, Ludwig Maximilians University, Munich; Sebastian Bauer, Sarcoma Center, West German Cancer Center, Essen; and Eva Wardelmann, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany
| | - Annette Reichardt
- Heikki Joensuu and Petri Bono, Comprehensive Cancer Center Helsinki; Heikki Joensuu, Harri Sihto, and Petri Bono, University of Helsinki, Helsinki; Raija Kallio, Oulu University Hospital, Oulu; Jouni Junnila, 4Pharma, Turku, Finland; Mikael Eriksson and Thor Alvegård, Lund University, Lund; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Kirsten Sundby Hall, Oslo University Hospital, Oslo, Norway; Annette Reichardt, Daniel Pink, and Peter Reichardt, Sarkomzentrum Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Berlin; Jörg T. Hartmann, Franziskus Hospital, Catholic Hospital Consortium Ostwestfalen, Bielefeld; Giuliano Ramadori, University of Göttingen, Göttingen; Peter Hohenberger, Mannheim University Medical Center, Mannheim; Salah-Eddin Al-Batran, Klinik für Onkologie und Hämatologie am Krankenhaus Nordwest, Frankfurt; Marcus Schlemmer, University Hospital Großhadern, Ludwig Maximilians University, Munich; Sebastian Bauer, Sarcoma Center, West German Cancer Center, Essen; and Eva Wardelmann, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany
| | - Jörg T Hartmann
- Heikki Joensuu and Petri Bono, Comprehensive Cancer Center Helsinki; Heikki Joensuu, Harri Sihto, and Petri Bono, University of Helsinki, Helsinki; Raija Kallio, Oulu University Hospital, Oulu; Jouni Junnila, 4Pharma, Turku, Finland; Mikael Eriksson and Thor Alvegård, Lund University, Lund; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Kirsten Sundby Hall, Oslo University Hospital, Oslo, Norway; Annette Reichardt, Daniel Pink, and Peter Reichardt, Sarkomzentrum Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Berlin; Jörg T. Hartmann, Franziskus Hospital, Catholic Hospital Consortium Ostwestfalen, Bielefeld; Giuliano Ramadori, University of Göttingen, Göttingen; Peter Hohenberger, Mannheim University Medical Center, Mannheim; Salah-Eddin Al-Batran, Klinik für Onkologie und Hämatologie am Krankenhaus Nordwest, Frankfurt; Marcus Schlemmer, University Hospital Großhadern, Ludwig Maximilians University, Munich; Sebastian Bauer, Sarcoma Center, West German Cancer Center, Essen; and Eva Wardelmann, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany
| | - Daniel Pink
- Heikki Joensuu and Petri Bono, Comprehensive Cancer Center Helsinki; Heikki Joensuu, Harri Sihto, and Petri Bono, University of Helsinki, Helsinki; Raija Kallio, Oulu University Hospital, Oulu; Jouni Junnila, 4Pharma, Turku, Finland; Mikael Eriksson and Thor Alvegård, Lund University, Lund; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Kirsten Sundby Hall, Oslo University Hospital, Oslo, Norway; Annette Reichardt, Daniel Pink, and Peter Reichardt, Sarkomzentrum Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Berlin; Jörg T. Hartmann, Franziskus Hospital, Catholic Hospital Consortium Ostwestfalen, Bielefeld; Giuliano Ramadori, University of Göttingen, Göttingen; Peter Hohenberger, Mannheim University Medical Center, Mannheim; Salah-Eddin Al-Batran, Klinik für Onkologie und Hämatologie am Krankenhaus Nordwest, Frankfurt; Marcus Schlemmer, University Hospital Großhadern, Ludwig Maximilians University, Munich; Sebastian Bauer, Sarcoma Center, West German Cancer Center, Essen; and Eva Wardelmann, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany
| | - Giuliano Ramadori
- Heikki Joensuu and Petri Bono, Comprehensive Cancer Center Helsinki; Heikki Joensuu, Harri Sihto, and Petri Bono, University of Helsinki, Helsinki; Raija Kallio, Oulu University Hospital, Oulu; Jouni Junnila, 4Pharma, Turku, Finland; Mikael Eriksson and Thor Alvegård, Lund University, Lund; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Kirsten Sundby Hall, Oslo University Hospital, Oslo, Norway; Annette Reichardt, Daniel Pink, and Peter Reichardt, Sarkomzentrum Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Berlin; Jörg T. Hartmann, Franziskus Hospital, Catholic Hospital Consortium Ostwestfalen, Bielefeld; Giuliano Ramadori, University of Göttingen, Göttingen; Peter Hohenberger, Mannheim University Medical Center, Mannheim; Salah-Eddin Al-Batran, Klinik für Onkologie und Hämatologie am Krankenhaus Nordwest, Frankfurt; Marcus Schlemmer, University Hospital Großhadern, Ludwig Maximilians University, Munich; Sebastian Bauer, Sarcoma Center, West German Cancer Center, Essen; and Eva Wardelmann, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany
| | - Peter Hohenberger
- Heikki Joensuu and Petri Bono, Comprehensive Cancer Center Helsinki; Heikki Joensuu, Harri Sihto, and Petri Bono, University of Helsinki, Helsinki; Raija Kallio, Oulu University Hospital, Oulu; Jouni Junnila, 4Pharma, Turku, Finland; Mikael Eriksson and Thor Alvegård, Lund University, Lund; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Kirsten Sundby Hall, Oslo University Hospital, Oslo, Norway; Annette Reichardt, Daniel Pink, and Peter Reichardt, Sarkomzentrum Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Berlin; Jörg T. Hartmann, Franziskus Hospital, Catholic Hospital Consortium Ostwestfalen, Bielefeld; Giuliano Ramadori, University of Göttingen, Göttingen; Peter Hohenberger, Mannheim University Medical Center, Mannheim; Salah-Eddin Al-Batran, Klinik für Onkologie und Hämatologie am Krankenhaus Nordwest, Frankfurt; Marcus Schlemmer, University Hospital Großhadern, Ludwig Maximilians University, Munich; Sebastian Bauer, Sarcoma Center, West German Cancer Center, Essen; and Eva Wardelmann, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany
| | - Salah-Eddin Al-Batran
- Heikki Joensuu and Petri Bono, Comprehensive Cancer Center Helsinki; Heikki Joensuu, Harri Sihto, and Petri Bono, University of Helsinki, Helsinki; Raija Kallio, Oulu University Hospital, Oulu; Jouni Junnila, 4Pharma, Turku, Finland; Mikael Eriksson and Thor Alvegård, Lund University, Lund; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Kirsten Sundby Hall, Oslo University Hospital, Oslo, Norway; Annette Reichardt, Daniel Pink, and Peter Reichardt, Sarkomzentrum Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Berlin; Jörg T. Hartmann, Franziskus Hospital, Catholic Hospital Consortium Ostwestfalen, Bielefeld; Giuliano Ramadori, University of Göttingen, Göttingen; Peter Hohenberger, Mannheim University Medical Center, Mannheim; Salah-Eddin Al-Batran, Klinik für Onkologie und Hämatologie am Krankenhaus Nordwest, Frankfurt; Marcus Schlemmer, University Hospital Großhadern, Ludwig Maximilians University, Munich; Sebastian Bauer, Sarcoma Center, West German Cancer Center, Essen; and Eva Wardelmann, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany
| | - Marcus Schlemmer
- Heikki Joensuu and Petri Bono, Comprehensive Cancer Center Helsinki; Heikki Joensuu, Harri Sihto, and Petri Bono, University of Helsinki, Helsinki; Raija Kallio, Oulu University Hospital, Oulu; Jouni Junnila, 4Pharma, Turku, Finland; Mikael Eriksson and Thor Alvegård, Lund University, Lund; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Kirsten Sundby Hall, Oslo University Hospital, Oslo, Norway; Annette Reichardt, Daniel Pink, and Peter Reichardt, Sarkomzentrum Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Berlin; Jörg T. Hartmann, Franziskus Hospital, Catholic Hospital Consortium Ostwestfalen, Bielefeld; Giuliano Ramadori, University of Göttingen, Göttingen; Peter Hohenberger, Mannheim University Medical Center, Mannheim; Salah-Eddin Al-Batran, Klinik für Onkologie und Hämatologie am Krankenhaus Nordwest, Frankfurt; Marcus Schlemmer, University Hospital Großhadern, Ludwig Maximilians University, Munich; Sebastian Bauer, Sarcoma Center, West German Cancer Center, Essen; and Eva Wardelmann, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany
| | - Sebastian Bauer
- Heikki Joensuu and Petri Bono, Comprehensive Cancer Center Helsinki; Heikki Joensuu, Harri Sihto, and Petri Bono, University of Helsinki, Helsinki; Raija Kallio, Oulu University Hospital, Oulu; Jouni Junnila, 4Pharma, Turku, Finland; Mikael Eriksson and Thor Alvegård, Lund University, Lund; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Kirsten Sundby Hall, Oslo University Hospital, Oslo, Norway; Annette Reichardt, Daniel Pink, and Peter Reichardt, Sarkomzentrum Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Berlin; Jörg T. Hartmann, Franziskus Hospital, Catholic Hospital Consortium Ostwestfalen, Bielefeld; Giuliano Ramadori, University of Göttingen, Göttingen; Peter Hohenberger, Mannheim University Medical Center, Mannheim; Salah-Eddin Al-Batran, Klinik für Onkologie und Hämatologie am Krankenhaus Nordwest, Frankfurt; Marcus Schlemmer, University Hospital Großhadern, Ludwig Maximilians University, Munich; Sebastian Bauer, Sarcoma Center, West German Cancer Center, Essen; and Eva Wardelmann, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany
| | - Eva Wardelmann
- Heikki Joensuu and Petri Bono, Comprehensive Cancer Center Helsinki; Heikki Joensuu, Harri Sihto, and Petri Bono, University of Helsinki, Helsinki; Raija Kallio, Oulu University Hospital, Oulu; Jouni Junnila, 4Pharma, Turku, Finland; Mikael Eriksson and Thor Alvegård, Lund University, Lund; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Kirsten Sundby Hall, Oslo University Hospital, Oslo, Norway; Annette Reichardt, Daniel Pink, and Peter Reichardt, Sarkomzentrum Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Berlin; Jörg T. Hartmann, Franziskus Hospital, Catholic Hospital Consortium Ostwestfalen, Bielefeld; Giuliano Ramadori, University of Göttingen, Göttingen; Peter Hohenberger, Mannheim University Medical Center, Mannheim; Salah-Eddin Al-Batran, Klinik für Onkologie und Hämatologie am Krankenhaus Nordwest, Frankfurt; Marcus Schlemmer, University Hospital Großhadern, Ludwig Maximilians University, Munich; Sebastian Bauer, Sarcoma Center, West German Cancer Center, Essen; and Eva Wardelmann, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany
| | - Bengt Nilsson
- Heikki Joensuu and Petri Bono, Comprehensive Cancer Center Helsinki; Heikki Joensuu, Harri Sihto, and Petri Bono, University of Helsinki, Helsinki; Raija Kallio, Oulu University Hospital, Oulu; Jouni Junnila, 4Pharma, Turku, Finland; Mikael Eriksson and Thor Alvegård, Lund University, Lund; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Kirsten Sundby Hall, Oslo University Hospital, Oslo, Norway; Annette Reichardt, Daniel Pink, and Peter Reichardt, Sarkomzentrum Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Berlin; Jörg T. Hartmann, Franziskus Hospital, Catholic Hospital Consortium Ostwestfalen, Bielefeld; Giuliano Ramadori, University of Göttingen, Göttingen; Peter Hohenberger, Mannheim University Medical Center, Mannheim; Salah-Eddin Al-Batran, Klinik für Onkologie und Hämatologie am Krankenhaus Nordwest, Frankfurt; Marcus Schlemmer, University Hospital Großhadern, Ludwig Maximilians University, Munich; Sebastian Bauer, Sarcoma Center, West German Cancer Center, Essen; and Eva Wardelmann, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany
| | - Harri Sihto
- Heikki Joensuu and Petri Bono, Comprehensive Cancer Center Helsinki; Heikki Joensuu, Harri Sihto, and Petri Bono, University of Helsinki, Helsinki; Raija Kallio, Oulu University Hospital, Oulu; Jouni Junnila, 4Pharma, Turku, Finland; Mikael Eriksson and Thor Alvegård, Lund University, Lund; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Kirsten Sundby Hall, Oslo University Hospital, Oslo, Norway; Annette Reichardt, Daniel Pink, and Peter Reichardt, Sarkomzentrum Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Berlin; Jörg T. Hartmann, Franziskus Hospital, Catholic Hospital Consortium Ostwestfalen, Bielefeld; Giuliano Ramadori, University of Göttingen, Göttingen; Peter Hohenberger, Mannheim University Medical Center, Mannheim; Salah-Eddin Al-Batran, Klinik für Onkologie und Hämatologie am Krankenhaus Nordwest, Frankfurt; Marcus Schlemmer, University Hospital Großhadern, Ludwig Maximilians University, Munich; Sebastian Bauer, Sarcoma Center, West German Cancer Center, Essen; and Eva Wardelmann, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany
| | - Petri Bono
- Heikki Joensuu and Petri Bono, Comprehensive Cancer Center Helsinki; Heikki Joensuu, Harri Sihto, and Petri Bono, University of Helsinki, Helsinki; Raija Kallio, Oulu University Hospital, Oulu; Jouni Junnila, 4Pharma, Turku, Finland; Mikael Eriksson and Thor Alvegård, Lund University, Lund; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Kirsten Sundby Hall, Oslo University Hospital, Oslo, Norway; Annette Reichardt, Daniel Pink, and Peter Reichardt, Sarkomzentrum Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Berlin; Jörg T. Hartmann, Franziskus Hospital, Catholic Hospital Consortium Ostwestfalen, Bielefeld; Giuliano Ramadori, University of Göttingen, Göttingen; Peter Hohenberger, Mannheim University Medical Center, Mannheim; Salah-Eddin Al-Batran, Klinik für Onkologie und Hämatologie am Krankenhaus Nordwest, Frankfurt; Marcus Schlemmer, University Hospital Großhadern, Ludwig Maximilians University, Munich; Sebastian Bauer, Sarcoma Center, West German Cancer Center, Essen; and Eva Wardelmann, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany
| | - Raija Kallio
- Heikki Joensuu and Petri Bono, Comprehensive Cancer Center Helsinki; Heikki Joensuu, Harri Sihto, and Petri Bono, University of Helsinki, Helsinki; Raija Kallio, Oulu University Hospital, Oulu; Jouni Junnila, 4Pharma, Turku, Finland; Mikael Eriksson and Thor Alvegård, Lund University, Lund; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Kirsten Sundby Hall, Oslo University Hospital, Oslo, Norway; Annette Reichardt, Daniel Pink, and Peter Reichardt, Sarkomzentrum Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Berlin; Jörg T. Hartmann, Franziskus Hospital, Catholic Hospital Consortium Ostwestfalen, Bielefeld; Giuliano Ramadori, University of Göttingen, Göttingen; Peter Hohenberger, Mannheim University Medical Center, Mannheim; Salah-Eddin Al-Batran, Klinik für Onkologie und Hämatologie am Krankenhaus Nordwest, Frankfurt; Marcus Schlemmer, University Hospital Großhadern, Ludwig Maximilians University, Munich; Sebastian Bauer, Sarcoma Center, West German Cancer Center, Essen; and Eva Wardelmann, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany
| | - Jouni Junnila
- Heikki Joensuu and Petri Bono, Comprehensive Cancer Center Helsinki; Heikki Joensuu, Harri Sihto, and Petri Bono, University of Helsinki, Helsinki; Raija Kallio, Oulu University Hospital, Oulu; Jouni Junnila, 4Pharma, Turku, Finland; Mikael Eriksson and Thor Alvegård, Lund University, Lund; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Kirsten Sundby Hall, Oslo University Hospital, Oslo, Norway; Annette Reichardt, Daniel Pink, and Peter Reichardt, Sarkomzentrum Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Berlin; Jörg T. Hartmann, Franziskus Hospital, Catholic Hospital Consortium Ostwestfalen, Bielefeld; Giuliano Ramadori, University of Göttingen, Göttingen; Peter Hohenberger, Mannheim University Medical Center, Mannheim; Salah-Eddin Al-Batran, Klinik für Onkologie und Hämatologie am Krankenhaus Nordwest, Frankfurt; Marcus Schlemmer, University Hospital Großhadern, Ludwig Maximilians University, Munich; Sebastian Bauer, Sarcoma Center, West German Cancer Center, Essen; and Eva Wardelmann, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany
| | - Thor Alvegård
- Heikki Joensuu and Petri Bono, Comprehensive Cancer Center Helsinki; Heikki Joensuu, Harri Sihto, and Petri Bono, University of Helsinki, Helsinki; Raija Kallio, Oulu University Hospital, Oulu; Jouni Junnila, 4Pharma, Turku, Finland; Mikael Eriksson and Thor Alvegård, Lund University, Lund; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Kirsten Sundby Hall, Oslo University Hospital, Oslo, Norway; Annette Reichardt, Daniel Pink, and Peter Reichardt, Sarkomzentrum Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Berlin; Jörg T. Hartmann, Franziskus Hospital, Catholic Hospital Consortium Ostwestfalen, Bielefeld; Giuliano Ramadori, University of Göttingen, Göttingen; Peter Hohenberger, Mannheim University Medical Center, Mannheim; Salah-Eddin Al-Batran, Klinik für Onkologie und Hämatologie am Krankenhaus Nordwest, Frankfurt; Marcus Schlemmer, University Hospital Großhadern, Ludwig Maximilians University, Munich; Sebastian Bauer, Sarcoma Center, West German Cancer Center, Essen; and Eva Wardelmann, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany
| | - Peter Reichardt
- Heikki Joensuu and Petri Bono, Comprehensive Cancer Center Helsinki; Heikki Joensuu, Harri Sihto, and Petri Bono, University of Helsinki, Helsinki; Raija Kallio, Oulu University Hospital, Oulu; Jouni Junnila, 4Pharma, Turku, Finland; Mikael Eriksson and Thor Alvegård, Lund University, Lund; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Kirsten Sundby Hall, Oslo University Hospital, Oslo, Norway; Annette Reichardt, Daniel Pink, and Peter Reichardt, Sarkomzentrum Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Berlin; Jörg T. Hartmann, Franziskus Hospital, Catholic Hospital Consortium Ostwestfalen, Bielefeld; Giuliano Ramadori, University of Göttingen, Göttingen; Peter Hohenberger, Mannheim University Medical Center, Mannheim; Salah-Eddin Al-Batran, Klinik für Onkologie und Hämatologie am Krankenhaus Nordwest, Frankfurt; Marcus Schlemmer, University Hospital Großhadern, Ludwig Maximilians University, Munich; Sebastian Bauer, Sarcoma Center, West German Cancer Center, Essen; and Eva Wardelmann, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany
| |
Collapse
|
14
|
Scalercio SRRA, Brito AB, Domingues SFS, Santos RR, Amorim CA. Immunolocalization of growth, inhibitory, and proliferative factors involved in initial ovarian folliculogenesis from adult common squirrel monkey (Saimiri collinsi). Reprod Sci 2014; 22:68-74. [PMID: 24784715 DOI: 10.1177/1933719114532842] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
We performed an immunohistochemical (IHC) study to determine the follicular expression of growth differentiation factor 9 (GDF-9), anti-Müllerian hormone (AMH), Kit Ligand (KL), and c-Kit in squirrel monkey ovary. Ovarian tissue fragments from 4 squirrel monkeys were collected by laparotomy and processed for classical histology and IHC. Additionally, follicle development was assessed by Ki67 immunostaining to evaluate proliferative status of granulosa cells. A total of 4025 follicles were examined (1475 for classical histology and 2550 for immunohistochemistry). More than 80% of the evaluated follicles were morphologically normal. The GDF-9 protein was detectable in oocyte cytoplasm from primordial (100%), primary (99.1%), and secondary (100%) follicles. The AMH was not expressed in primordial follicles but just in few primary follicles (13.8%). On the other hand, it was highly expressed in granulosa cells from secondary follicles (67.9%). c-Kit, KL receptor, was found in the oolemma of primordial (100%), primary (100%), and secondary (100%) follicles. The KL expression was observed in oocytes and granulosa cells from primordial (94.9%), primary (91.6%) and secondary follicles (100%). Ki67 immunostaining was observed in granulosa cells from primary (5.7%) and secondary (54.8%) follicles but not in primordial follicles. In conclusion, we described the localization of GDF-9, KL, c-Kit, and Ki67 proteins and confirmed the presence of AMH protein in preantral follicles from squirrel monkey. Our results offer contribution for understanding of folliculogenesis in neotropical nonhuman primates. Moreover, these markers can be used to assess follicular viability and functionality after cryopreservation, transplantation, or in vitro culture of ovarian tissue.
Collapse
Affiliation(s)
- S R R A Scalercio
- Laboratory of Wild Animal Biology and Medicine, Federal University of Pará, Castanhal, Pará, Brazil Animal Sciences PhD Program, Federal University of Pará, Belém, Pará, Brazil National Primate Centre, Secretary of Health Policy, Ministry of Health, Ananindeua, Pará, Brazil
| | - A B Brito
- Laboratory of Wild Animal Biology and Medicine, Federal University of Pará, Castanhal, Pará, Brazil Animal Sciences PhD Program, Federal University of Pará, Belém, Pará, Brazil
| | - S F S Domingues
- Laboratory of Wild Animal Biology and Medicine, Federal University of Pará, Castanhal, Pará, Brazil Animal Sciences PhD Program, Federal University of Pará, Belém, Pará, Brazil
| | - R R Santos
- Laboratory of Wild Animal Biology and Medicine, Federal University of Pará, Castanhal, Pará, Brazil Animal Sciences PhD Program, Federal University of Pará, Belém, Pará, Brazil Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands
| | - C A Amorim
- Pôle de Recherche en Gynécologie, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium
| |
Collapse
|
15
|
Aguilar C, Aguilar C, Lopez-Marure R, Jiménez-Sánchez A, Rocha-Zavaleta L. Co-stimulation with stem cell factor and erythropoietin enhances migration of c-Kit expressing cervical cancer cells through the sustained activation of ERK1/2. Mol Med Rep 2014; 9:1895-902. [PMID: 24626629 DOI: 10.3892/mmr.2014.2044] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2013] [Accepted: 02/17/2014] [Indexed: 11/06/2022] Open
Abstract
The cytokines erythropoietin (Epo) and stem cell factor (SCF), coupled with the cooperation between their receptors (EpoR and c-Kit), are essential components of normal physiological erythropoiesis. In earlier studies, we demonstrated the expression of c-Kit and EpoR in cervical cancer cells. It was identified that SCF is a survival factor, whereas Epo promotes cell proliferation. Cooperation between EpoR and SCF in cervical cancer has rarely been studied, despite the fact that cell migration and anchorage independent growth are considered initial steps in metastasis. Thus, the aim of this study was to analyse the effect of SCF and Epo alone, or in combination, on the migration and anchorage independent growth of two cervical cancer-derived cell lines. First, we demonstrated the expression of EpoR and c-Kit in the cell lines. Next, we evaluated anchorage independent growth, and identified that Epo and SCF produced a modest number of colonies, whereas the combination Epo/SCF induced a significantly higher number of colonies. Migration was then evaluated in Boyden chambers. Co-stimulation with Epo/SCF induced a significantly higher number of migrating cells than either cytokine alone. SCF-, Epo- and Epo/SCF-induced migration was inhibited by blocking phosphorylation of Janus kinase 2 (JAK2). Accordingly, western blot analysis demonstrated that the JAK2/signal transducer and activator of transcription-5 (STAT5) axis was activated in all cases. By contrast, inhibition of extracellular signal-related kinase (ERK) 1/2 abrogated migration induced by SCF and Epo/SCF only. Concurrently, Epo induced a modest, transient activation of ERK1/2, whereas SCF and Epo/SCF prompted a strong, sustained phosphorylation of ERK1/2. The results from this study have revealed that co-stimulation with Epo/SCF promotes migration and anchorage independent cell growth, and that co-signalling from EpoR and c-Kit converge on JAK2/STAT5 activation. Furthermore, SCF- and Epo/SCF-induced migration depends on the sustained activation of ERK1/2. These results indicate that co-signalling from different cytokine receptors induces migration, and this suggests that migratory behaviour may be regulated by the cooperative activity of Epo and SCF in cells expressing their cognate receptors.
Collapse
Affiliation(s)
- Cristina Aguilar
- Instituto de Investigaciones Biomédicas, Departamento de Biología Molecular y Biotecnología, UNAM, Ciudad Universitaria, C.P. 04510, Mexico City, Mexico
| | - Cecilia Aguilar
- Instituto de Investigaciones Biomédicas, Departamento de Biología Molecular y Biotecnología, UNAM, Ciudad Universitaria, C.P. 04510, Mexico City, Mexico
| | - Rebeca Lopez-Marure
- Instituto Nacional de Cardiología 'Ignacio Chávez', Departamento de Biología Celular, Colonia Sección 16, Tlalpan, C.P. 14080, Mexico City, Mexico
| | - Alejandro Jiménez-Sánchez
- Instituto de Investigaciones Biomédicas, Departamento de Biología Molecular y Biotecnología, UNAM, Ciudad Universitaria, C.P. 04510, Mexico City, Mexico
| | - Leticia Rocha-Zavaleta
- Instituto de Investigaciones Biomédicas, Departamento de Biología Molecular y Biotecnología, UNAM, Ciudad Universitaria, C.P. 04510, Mexico City, Mexico
| |
Collapse
|
16
|
Interstitial cells of Cajal integrate excitatory and inhibitory neurotransmission with intestinal slow-wave activity. Nat Commun 2013; 4:1630. [PMID: 23535651 DOI: 10.1038/ncomms2626] [Citation(s) in RCA: 155] [Impact Index Per Article: 14.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2012] [Accepted: 02/20/2013] [Indexed: 12/27/2022] Open
Abstract
The enteric nervous system contains excitatory and inhibitory neurons, which control contraction and relaxation of smooth muscle cells as well as gastrointestinal motor activity. Little is known about the exact cellular mechanisms of neuronal signal transduction to smooth muscle cells in the gut. Here we generate a c-Kit(CreERT2) knock-in allele to target a distinct population of pacemaker cells called interstitial cells of Cajal. By genetic loss-of-function studies, we show that interstitial cells of Cajal, which generate spontaneous electrical slow waves and thus rhythmic contractions of the smooth musculature, are essential for transmission of signals from enteric neurons to gastrointestinal smooth muscle cells. Interstitial cells of Cajal, therefore, integrate excitatory and inhibitory neurotransmission with slow-wave activity to orchestrate peristaltic motor activity of the gut. Impairment of the function of interstitial cells of Cajal causes severe gastrointestinal motor disorders. The results of our study show at the genetic level that these disorders are not only due to loss of slow-wave activity but also due to disturbed neurotransmission.
Collapse
|
17
|
Gavert N, Shvab A, Sheffer M, Ben-Shmuel A, Haase G, Bakos E, Domany E, Ben-Ze'ev A. c-Kit is suppressed in human colon cancer tissue and contributes to L1-mediated metastasis. Cancer Res 2013; 73:5754-63. [PMID: 24008320 DOI: 10.1158/0008-5472.can-13-0576] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The transmembrane neural cell adhesion receptor L1 is a Wnt/β-catenin target gene expressed in many tumor types. In human colorectal cancer, L1 localizes preferentially to the invasive front of tumors and when overexpressed in colorectal cancer cells, it facilitates their metastasis to the liver. In this study, we investigated genes that are regulated in human colorectal cancer and by the L1-NF-κB pathway that has been implicated in liver metastasis. c-Kit was the most highly suppressed gene in both colorectal cancer tissue and the L1-NF-κB pathway. c-Kit suppression that resulted from L1-mediated signaling relied upon NF-κB, which directly inhibited the transcription of SP1, a major activator of the c-Kit gene promoter. Reconstituting c-Kit expression in L1-transfected cells blocked the biological effects conferred by L1 overexpression in driving motility and liver metastasis. We found that c-Kit expression in colorectal cancer cells is associated with a more pronounced epithelial morphology, along with increased expression of E-cadherin and decreased expression of Slug. Although c-Kit overexpression inhibited the motility and metastasis of L1-expressing colorectal cancer cells, it enhanced colorectal cancer cell proliferation and tumorigenesis, arguing that separate pathways mediate tumorigenicity and metastasis by c-Kit. Our findings provide insights into how colorectal cancer metastasizes to the liver, the most common site of dissemination in this cancer.
Collapse
Affiliation(s)
- Nancy Gavert
- Authors' Affiliations: Departments of Molecular Cell Biology; and Physics and Complex Systems, The Weizmann Institute of Science Rehovot, Israel
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Gfroerer S, Rolle U. Interstitial cells of Cajal in the normal human gut and in Hirschsprung disease. Pediatr Surg Int 2013; 29:889-97. [PMID: 23917331 DOI: 10.1007/s00383-013-3364-y] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Hirschsprung disease (HD) is the most prevalent congenital gastrointestinal motility disorder. The pathogenesis of HD is defined as a functional intestinal obstruction resulting from a defect in the intrinsic innervation of the distal bowel. In addition to the enteric nervous system, the interstitial cells of Cajal (ICC) play an important role in the generation of coordinated gastrointestinal peristalsis. The major function of the ICCs is the generation of slow waves that allow these cells to act as specialised pacemaker cells within various tissues. ICCs have additional functions in the gastrointestinal tract as regulators of mechanical activity and neurotransmission. Due to the central role of ICCs in gastrointestinal peristalsis, it has been suggested that defects or impairments of the ICCs may contribute to motility dysfunction in several gastrointestinal motility disorders. This review describes the distribution and functions of ICCs in the normal gut and in Hirschsprung disease.
Collapse
Affiliation(s)
- Stefan Gfroerer
- Department of Paediatric Surgery, University Hospital, Goethe University Frankfurt/M, 60596 Frankfurt/M, Germany,
| | | |
Collapse
|
19
|
Celik O, Celik E, Yilmaz E, Celik N, Turkcuoglu I, Ulas M, Kumbak B, Aktan E, Ozerol I. Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin-releasing hormone agonist and antagonists, on follicular fluid stem cell factor and serum urocortin 1 levels on the day of oocyte retrieval. Arch Gynecol Obstet 2013; 288:1417-22. [PMID: 23801011 DOI: 10.1007/s00404-013-2804-1] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2012] [Accepted: 03/12/2013] [Indexed: 11/24/2022]
Abstract
PURPOSE To compare the serum and follicular fluid (FF) concentrations of stem cell factor (SCF) as well as the serum urocortin 1 (UCN1) concentration in gonadotropin-releasing hormone antagonist (GnRH-ant) and gonadotropin-releasing hormone agonist (GnRH-a) protocols for controlled ovarian hyperstimulation (COH) in IVF patients. METHODS Follicular fluids and blood samples of 42 infertile women undergoing COH for IVF-embryo transfer with either GnRH agonist (n = 22) or GnRH antagonist (n = 20) protocols from 2010 to 2011 were collected during oocyte retrieval. SCF concentrations of serum and FF were assessed by sandwich enzyme immunoassay using ELISA Kit for SCF kid. Serum UCN1 concentration were measured using commercially available enzyme-linked immunosorbent assay. RESULTS Concentrations of serum UCN1, serum and FF SCF were similar in the two groups. The serum SCF levels correlated strongly with the follicular SCF levels (r = 0.770, p < 0.001). The mean implantation rate, biochemical and clinical pregnancy rate and live birth rate per cycle were also similar in the groups. CONCLUSIONS These observations suggest that there is no significant difference in follicular microenvironment in terms of SCF and UCN1 between agonist and antagonist protocols.
Collapse
Affiliation(s)
- Onder Celik
- Department of Obstetrics and Gynecology, Inonu University, Turgut Ozal Medical Center, 44069, Malatya, Turkey,
| | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Dumesic DA, Richards JS. Ontogeny of the ovary in polycystic ovary syndrome. Fertil Steril 2013; 100:23-38. [PMID: 23472949 DOI: 10.1016/j.fertnstert.2013.02.011] [Citation(s) in RCA: 55] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2012] [Revised: 02/05/2013] [Accepted: 02/06/2013] [Indexed: 12/11/2022]
Abstract
Activation of primordial follicles into the growing pool, selection of the dominant follicle, and its eventual ovulation require complex endocrine and metabolic interactions as well as intraovarian paracrine signals to coordinate granulosa cell proliferation, theca cell differentiation, and oocyte maturation. Early preantral follicle development relies mostly upon mesenchymal-epithelial cell interactions, intraovarian paracrine signals, and oocyte-secreted factors, whereas development of the antral follicle depends on circulating gonadotropins as well as locally derived regulators. In women with polycystic ovary syndrome (PCOS), ovarian hyperandrogenism, hyperinsulinemia from insulin resistance, and altered intrafollicular paracrine signaling perturb the activation, survival, growth, and selection of follicles, causing accumulation of small antral follicles within the periphery of the ovary, giving it a polycystic morphology. Altered adipocyte-ovarian interactions further compound these adverse events on follicle development and also can harm the oocyte, particularly in the presence of increased adiposity. Finally, endocrine antecedents of PCOS occur in female infants born to mothers with PCOS, which suggests that interactions between genes and the maternal-fetal hormonal environment may program ovarian function after birth.
Collapse
Affiliation(s)
- Daniel A Dumesic
- Department of Obstetrics and Gynecology, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA.
| | | |
Collapse
|
21
|
Abstract
Various physiologically relevant processes are regulated by the interaction of the receptor tyrosine kinase (c-Kit) and its ligand stem cell factor (SCF), with SCF known to be the most important growth factor for mast cells (MCs). In spite of their traditional role in allergic disorders and innate immunity, MCs have lately emerged as versatile modulators of a variety of physiologic and pathologic processes. Here we show that MCs are critical for pregnancy success. Uterine MCs presented a unique phenotype, accumulated during receptivity and expanded upon pregnancy establishment. KitW-sh/W-sh mice, whose MC deficiency is based on restricted c-Kit gene expression, exhibited severely impaired implantation, which could be completely rescued by systemic or local transfer of wild-type bone marrow-derived MCs. Transferred wild-type MCs favored normal implantation, induced optimal spiral artery remodeling and promoted the expression of MC proteases, transforming growth factor-β and connective tissue growth factor. MCs contributed to trophoblast survival, placentation and fetal growth through secretion of the glycan-binding protein galectin-1. Our data unveil unrecognized roles for MCs at the fetomaternal interface with critical implications in reproductive medicine.
Collapse
|
22
|
Cells with stem cell characteristics in somatic compartments of the ovary. BIOMED RESEARCH INTERNATIONAL 2012; 2013:310859. [PMID: 23484108 PMCID: PMC3591217 DOI: 10.1155/2013/310859] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/27/2012] [Revised: 11/26/2012] [Accepted: 11/27/2012] [Indexed: 11/28/2022]
Abstract
Antral follicular growth in the ovary is characterized by rapid expansion of granulosa cells accompanied by a rising complexity of their functionality. Within two weeks the number of human granulosa cells increases from less than 500,000 to more than 50 millions cells per follicle and differentiates into groups of cells with a variety of specialized functions involved in steroidogenesis, nursing the oocyte, and forming a functional syncitium. Both the rapid proliferation and different specialized functions of the granulosa cells can only be explained through the involvement of stem cells. However, luteinizing granulosa cells were believed to be terminally differentiated cells. Only recently, stem and progenitor cells with FSH-receptor activity were identified in populations of luteinizing granulosa cells obtained during oocyte collected for assisted reproduction. In the presence of the leukaemia-inhibiting factor (LIF), it was possible to culture a subpopulation of the luteinizing granulosa cells over prolonged time periods. Furthermore, when embedded in a matrix consisting of collagen type I, these cells continued to express the FSH receptor over prolonged time periods, developed globular formations that surrogated as follicle-like structures, providing a promising tool for reproductive biology.
Collapse
|
23
|
Raucci F, Di Fiore MM. Localization of c-kit and stem cell factor (SCF) in ovarian follicular epithelium of a lizard, Podarcis s. sicula. Acta Histochem 2011; 113:647-55. [PMID: 20850173 DOI: 10.1016/j.acthis.2010.08.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2010] [Revised: 08/16/2010] [Accepted: 08/17/2010] [Indexed: 10/19/2022]
Abstract
We performed an immunohistochemical study to determine the immunolocalization of c-kit and stem cell factor (SCF) in ovarian follicles during the reproductive cycle of the lizard, Podarcis s. sicula. Follicles were serially cut and used for histological and histochemical characterization and also for immunohistochemical detection of both c-kit and SCF. C-kit and SCF were localized in the follicles with a differing pattern with regard to the stage of sexual cycle or the cell type forming the follicular epithelium (granulosa). In pre-reproductive follicles, where the granulosa consists of three main different cytotypes, the c-kit receptor was prevalently localized on the plasmalemma of small cells, although some pyriform and intermediate cells also appeared positive. C-kit was also localized in the theca. In pre-reproductive follicles, SCF was markedly observed in the cytoplasm of some pyriform cells. Small cells and theca also stained moderately positive, whereas the intermediate cells were mostly negative. In reproductive follicles, where granulosa cells are morphologically rearranged, c-kit was observed in small cells and in some thecal elements, while SCF was weakly immunostained. At the site of follicular layer invaginations evident c-kit/SCF immunostaining was observed in the granulosa epithelium and in the theca. These observations suggest that the expression of c-kit and SCF changes as a function of follicular development and may reflect the involvement of this system in the maturation of the oocyte.
Collapse
|
24
|
Salmassi A, Zorn S, Mettler L, Koch K, Jonat W, Schmutzler AG. Circulating concentration of stem cell factor in serum of stimulated IVF patients. Reprod Biomed Online 2010; 22:140-7. [PMID: 21195027 DOI: 10.1016/j.rbmo.2010.10.008] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2010] [Revised: 10/12/2010] [Accepted: 10/13/2010] [Indexed: 11/28/2022]
Abstract
Stem cell factor (SCF) plays a major role in haematopoiesis and spermatogenesis, and possibly female fertility. This study investigated the role of changes in SCF concentrations in 74 assisted conception patients. In group 1 (n=74) SCF concentration was assessed in serum and follicular fluid (FF) on the day of follicular puncture (FP) and compared in serum and FF in response to ovarian stimulation between low (n=25), moderate (n=26) and high (n=14) responders. In group 2 (n=30) serum for SCF assessment was collected throughout the menstrual cycle until gestation. SCF concentration related to the number of follicles in serum and in FF decreased from low to moderate and high responders (P<0.001); pregnancy rates were 20.0%, 34.6% and 50.1%, respectively (P=0.05). SCF in serum increased from stimulation days 6-8 to 9-11 and peaked on the day of human chorionic gonadotrophin injection (P=0.03). The SCF concentrations dropped slightly on the day of FP, increased significantly to the day of pregnancy confirmation and reached highest concentration (P=0.02) during gestation. SCF is involved in follicle development and may be a predictor of IVF outcome.
Collapse
Affiliation(s)
- Ali Salmassi
- Centre for Reproductive Medicine, Women's Hospital, Christian-Albrechts-University, Arnold-Heller Strasse 3, Kiel, Germany.
| | | | | | | | | | | |
Collapse
|
25
|
Kidder GM, Vanderhyden BC. Bidirectional communication between oocytes and follicle cells: ensuring oocyte developmental competence. Can J Physiol Pharmacol 2010; 88:399-413. [PMID: 20555408 DOI: 10.1139/y10-009] [Citation(s) in RCA: 196] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Female fertility is determined to a large extent by the quality (developmental competence) of the oocyte as reflected in its ability to undergo meiosis, be fertilized, and give rise to a healthy embryo. Growth of the mammalian oocyte is coordinated with that of the follicle that encloses it by the actions of signals that pass in both directions between the germline and somatic components. This review summarizes what is known about the roles played by 2 different modes of intrafollicular signalling in oogenesis: paracrine factors activating receptors on the opposite cell type, and direct sharing of small molecules throughout the follicle via gap junction channels. Recent evidence indicates that these 2 modes of signalling interact to regulate oocyte growth and granulosa cell proliferation and that defects in either can contribute to female infertility.
Collapse
Affiliation(s)
- Gerald M Kidder
- Departments of Physiology and Pharmacology, Obstetrics and Gynaecology, and Paediatrics, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, ON N6A 5C1, Canada.
| | | |
Collapse
|
26
|
Jin ZW, Kim YG, Yu HC, Murakami G, Fujimiya M, Cho BH. A comparison between D2-40 and c-KIT immunohistochemistry for the human fetal testis and ovary at the second trimester of gestation. Okajimas Folia Anat Jpn 2010; 87:1-4. [PMID: 20715565 DOI: 10.2535/ofaj.87.1] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
Both M2A (D2-40) and c-KIT have frequently been used as markers of germ cell tumors. However, comparative studies of their immunoreactivities in human fetal gonads have been limited. Using horizontal semiserial whole-abdomen sections of 9 human abortuses at 12 weeks (2 males and 1 females; CRL 70-80 mm), 15 weeks (2 males and 3 females; 115-125 mm) and 18 weeks (1 female; 155 mm) of gestation, we identified germ cells in the testis and ovary on the basis of c-KIT immunoreactivity. M2A was also stained using near or adjacent sections. In 12-week fetuses, c-KIT immunoreactivity was weak, but M2A immunoreactivity was consistently strong. At 15 and 18 weeks of gestation, c-KIT immunoreactivity was found in most germ cells. M2A was expressed in Sertoli cells as well as in germ cells, but was not expressed in ovarian follicles undergoing meiosis. M2A appears to be a more useful marker of germ cells than c-KIT in human fetal testis and ovary at the second trimester. M2A is also reactive in fetal Sertoli cells, but its expression is consistently weaker than in germ cells.
Collapse
Affiliation(s)
- Zhe Wu Jin
- 'Department of Surgery and Research Institute of Clinical Medicine, Chonbuk National University Medical School, Jeonju, Korea
| | | | | | | | | | | |
Collapse
|
27
|
Gougeon A. Human ovarian follicular development: from activation of resting follicles to preovulatory maturation. ANNALES D'ENDOCRINOLOGIE 2010; 71:132-43. [PMID: 20362973 DOI: 10.1016/j.ando.2010.02.021] [Citation(s) in RCA: 128] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/12/2010] [Revised: 02/12/2010] [Accepted: 02/15/2010] [Indexed: 11/25/2022]
Abstract
By integrating morphometrical and endocrinological data, as well as biological effects of various molecules synthesized by the human follicle, we propose a dynamic view of the follicle growth within the human ovary. Folliculogenesis starts with entry of resting follicles into the growth phase, a process where the kit system plays a key role. Several months are required for a new growing follicle to reach the preantral stage (0.15mm), then 70 additional days to reach the size of 2mm. Early growing follicle growth is regulated by subtle interactions between follicle-stimulating hormone (FSH) and local factors produced by theca and granulosa cells (GCs), as well as the oocyte. From the time they enter the selectable stage during the late luteal phase, follicles become sensitive to cyclic changes of FSH in terms of granulosa cell proliferation. During the early follicular phase, the early selected follicle grows very quickly and estradiol is present in the follicular fluid. However, the total steroid production remains moderate. From the mid-follicular phase, the preovulatory follicle synthesizes high quantities of estradiol, then after the mid-cycle gonadotropin surge, very large amounts of progesterone. At this stage of development, the responsiveness of the follicle to gonadotropins is maximum, especially to luteinizing hormone (LH) that triggers granulosa wall dissociation and cumulus expansion as well as oocyte nuclear maturation. Thus, as the follicle develops, its responsiveness to gonadotropins progressively increases under the control of local factors acting in an autocrine/paracrine fashion.
Collapse
Affiliation(s)
- A Gougeon
- Inserm U865, Anipath, faculté de médecine Laënnec, 7, rue Guillaume-Paradin, 69372 Lyon cedex 08, France.
| |
Collapse
|
28
|
Application of stem cell markers in search for neoplastic germ cells in dysgenetic gonads, extragonadal tumours, and in semen of infertile men. Cancer Treat Rev 2008; 34:348-67. [PMID: 18289797 DOI: 10.1016/j.ctrv.2007.12.007] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2007] [Revised: 12/17/2007] [Accepted: 12/18/2007] [Indexed: 01/08/2023]
Abstract
Germ cell tumours (GCTs) are a complex entity. Current areas of attention include early detection and avoidance of unnecessary over-treatment. Novel findings regarding diagnosis of GCTs located in various anatomical sites are described, particularly testicular GCTs and their common progenitor, carcinoma in situ (CIS). Recognition of CIS enables intervention before tumour development, but nevertheless, testicular GCTs are sporadically diagnosed at the pre-invasive stage where minimal treatment is necessary. As presence of CIS is asymptomatic, a simple screening method is needed when CIS is suspected (i.e. in males investigated for infertility). To develop approaches for early detection CIS gene expression studies have been performed showing many similarities with embryonic stem cells with confirmation of established markers (i.e. PLAP, OCT-3/4, KIT) and identification of novel markers (i.e. AP-2 gamma, NANOG). We have reported a very promising new approach of AP-2 gamma (or OCT3/4) based immunocytological semen analysis (specificity 93.6%, sensitivity 54.5%). Comparative studies of gonadal/extragonadal GCTs have revealed resemblance pointing towards similar, but not identical, origins. Moreover, infertility and testicular cancer are connected in the 'Testicular Dysgenesis Syndrome' and 25% of contralateral testes from testicular GCT patients harbour dysgenetic features, including impaired spermatogenesis. Thus, recent data have provided potential diagnostic tools including CIS detection in semen, microarray-based tumour classification, additional serological GCT markers, and novel stem cell markers for immunohistochemical diagnosis of gonadal and extragonadal GCTs. Many CIS candidate genes are yet uninvestigated, and information from these could increase knowledge about CIS tumour initiation/progression and be used for optimisation of a non-invasive detection method.
Collapse
|
29
|
Abstract
Interstitial cells of Cajal (ICCs) are pacemaker cells which are densely distributed throughout the whole gastrointestinal tract. ICCs have important functions in neurotransmission, generation of slow waves and regulation of mechanical activities in the gastrointestinal tract, especially for the coordinated gastrointestinal peristalsis. Therefore, a loss of ICCs could result in gastrointestinal motor dysfunction. In recent years c-kit labeling has been widely used to study pathological changes of ICCs in gastrointestinal motility disorders. Paediatric gastrointestinal motility disorders such as hypertrophic pyloric stenosis, Hirschsprung's disease, total colonic aganglionosis, hypoganglionosis, intestinal neuronal dysplasia, internal anal sphincter achalasia, megacystis microcolon intestinal hypoperistalsis syndrome have been reported to be associated with loss or deficiency of ICCs networks. This review describes the distribution of ICCs in the normal gastrointestinal tract and its altered distribution in intestinal motility disorders of childhood.
Collapse
|
30
|
Chinen H, Matsuoka K, Sato T, Kamada N, Okamoto S, Hisamatsu T, Kobayashi T, Hasegawa H, Sugita A, Kinjo F, Fujita J, Hibi T. Lamina propria c-kit+ immune precursors reside in human adult intestine and differentiate into natural killer cells. Gastroenterology 2007; 133:559-73. [PMID: 17681176 DOI: 10.1053/j.gastro.2007.05.017] [Citation(s) in RCA: 77] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/13/2006] [Accepted: 04/26/2007] [Indexed: 12/13/2022]
Abstract
BACKGROUND AND AIMS Recent studies have revealed that murine intestinal mucosa contains several kinds of lineage markers (lin)(-) c-kit(+) immune precursor cells. However, immune precursors in the human adult intestine have not been studied extensively. METHODS Lamina propria mononuclear cells and intraepithelial lymphocytes from surgically resected human adult intestine were examined for the surface antigen expression and cytokine profile by immunohistochemistry and flow cytometry. The transcriptional profile of these cells was analyzed by reverse-transcription polymerase chain reaction. The phenotypic and functional characterization of the in vitro differentiating cells from the precursors was examined by flow cytometry. RESULTS We identified lin(-) c-kit(+) cells scattered throughout lamina propria of the human adult intestine. These intestinal immune precursors expressed CD34, CD38, CD33, interleukin-2R alpha, and interleukin-7R alpha, and they had much more abundant expression of Id2, PU.1, SpiB1, and lymphotoxin than thymocytes. The lin(-) c-kit(+) immune precursors mainly differentiated into CD56(+) c-kit(dim) cells during in vitro culture. These in vitro differentiating cells corresponded to intestinal natural killer (NK) cells, which had distinct characteristics from their peripheral counterparts, such as CD83 and integrin alpha(E) expression, less cytotoxic activity, and higher interferon-gamma production. Furthermore, both c-kit(dim) cells and NK cells were increased in lamina propria of Crohn's disease, although there was no change for peripheral blood NK cells. CONCLUSIONS The human intestine may have the unique NK cell differentiation system, which may contribute to maintenance of immune homeostasis in the intestine.
Collapse
MESH Headings
- ADP-ribosyl Cyclase 1/metabolism
- Adult Stem Cells/immunology
- Adult Stem Cells/metabolism
- Adult Stem Cells/pathology
- Antigens, CD/metabolism
- Antigens, CD34/metabolism
- Antigens, Differentiation, Myelomonocytic/metabolism
- CD56 Antigen/metabolism
- Cell Differentiation
- Cell Lineage
- Cells, Cultured
- Colitis, Ulcerative/genetics
- Colitis, Ulcerative/immunology
- Colitis, Ulcerative/metabolism
- Colitis, Ulcerative/pathology
- Crohn Disease/genetics
- Crohn Disease/immunology
- Crohn Disease/metabolism
- Crohn Disease/pathology
- DNA-Binding Proteins/genetics
- DNA-Binding Proteins/metabolism
- Gene Expression
- Hematopoietic Stem Cells/immunology
- Hematopoietic Stem Cells/metabolism
- Hematopoietic Stem Cells/pathology
- Humans
- Immunoglobulins/metabolism
- Immunophenotyping
- Inhibitor of Differentiation Protein 2/genetics
- Inhibitor of Differentiation Protein 2/metabolism
- Integrin alpha Chains/metabolism
- Interferon-gamma/metabolism
- Interleukin-2 Receptor alpha Subunit/metabolism
- Intestinal Mucosa/immunology
- Intestinal Mucosa/metabolism
- Intestinal Mucosa/pathology
- Killer Cells, Natural/immunology
- Killer Cells, Natural/metabolism
- Killer Cells, Natural/pathology
- Lymphotoxin-alpha/genetics
- Lymphotoxin-alpha/metabolism
- Membrane Glycoproteins/metabolism
- Proto-Oncogene Proteins/genetics
- Proto-Oncogene Proteins/metabolism
- Proto-Oncogene Proteins c-kit/metabolism
- RNA, Messenger/metabolism
- Receptors, Interleukin-7/metabolism
- Sialic Acid Binding Ig-like Lectin 3
- Time Factors
- Trans-Activators/genetics
- Trans-Activators/metabolism
- Transcription Factors/genetics
- Transcription Factors/metabolism
- CD83 Antigen
Collapse
Affiliation(s)
- Hiroshi Chinen
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Erdogan G, Bassorgun CI, Pestereli HE, Simsek T, Karaveli S. C-kit protein expression in uterine and ovarian mesenchymal tumours. APMIS 2007; 115:204-9. [PMID: 17367465 DOI: 10.1111/j.1600-0463.2007.apm_419.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The protooncogene c-kit encoding transmembrane tyrosine kinase receptor protein plays an important role in the signal transduction pathway that regulates cellular growth and repair. Gene product KIT overexpression has been shown in a number of different neoplasms, particularly in mastocytosis and gastrointestinal stromal tumours (GIST). The morphologic similarity of uterine mesenchymal tumours and GIST, and the presence of KIT protein in normal uterine tissue, suggests that uterine sarcomas may have the same c-kit overexpression. The purpose of this study was to determine the overexpression of c-kit protein in uterine and ovarian sarcomas. Immunohistochemical staining using a polyclonal anti-c-kit antibody was performed on tissue blocks from 12 carsinosarcomas, 14 leiomyosarcomas, 8 endometrial stromal sarcomas, 2 adenosarcomas, 1 atypical leiomyoma, 1 leiomyoma with limited experience, and 10 leiomyomas. The slides were evaluated by a semiquantitative method. C-kit was positive in 10 of 12 (83%) carcinosarcomas, 10 of 14 (71%) leiomyosarcomas, 6 of 8 75(%) endometrial stromal sarcomas, 1 of 2 (50%) adenosarcomas, 1 leiomyoma with limited experience, and 1 of 10 (10%) leiomyomas. The uterine sarcomas express c-kit, like GISTs. It seems that KIT may have a significant role in the oncogenesis of mesenchymal tumours of the uterus and ovary.
Collapse
Affiliation(s)
- Gülgün Erdogan
- Department of Pathology, Akdeniz University, Antalya, Turkey.
| | | | | | | | | |
Collapse
|
32
|
Day AS, Lou PJ, Lin WC, Chou CC. Over-expression of c-kit in a primary leiomyosarcoma of the thyroid gland. Eur Arch Otorhinolaryngol 2007; 264:705-8. [PMID: 17256123 DOI: 10.1007/s00405-007-0242-z] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2006] [Accepted: 12/09/2006] [Indexed: 11/30/2022]
Abstract
Primary leiomyosarcoma of the thyroid gland is rare. In this paper, we report a case of high-grade leiomyosarcoma of the thyroid gland in a 43-year-old man. Lung metastasis was also noted in this patient. Despite of aggressive surgical treatment, the patient died of uncontrolled local recurrent disease 6 months after the initial operation. Immunohistochemical studies showed the tumor cells were positive for c-kit proto-oncogene product. Imatinib mesylate was used as a post-operative adjuvant treatment but the response was poor. The role of tyrosine kinase inhibitors on the treatment of thyroid leiomyosarcomas is still unclear because this is the first report of c-kit over-expression in such tumors. Nevertheless, our results show that c-kit over-expression might not be an indicator of good response to imatinib mesylate treatment in thyroid leiomyosarcomas.
Collapse
Affiliation(s)
- An-Shiou Day
- Department of Otolaryngology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan, ROC
| | | | | | | |
Collapse
|
33
|
Hutt KJ, McLaughlin EA, Holland MK. KIT/KIT Ligand in Mammalian Oogenesis and Folliculogenesis: Roles in Rabbit and Murine Ovarian Follicle Activation and Oocyte Growth1. Biol Reprod 2006; 75:421-33. [PMID: 16790689 DOI: 10.1095/biolreprod.106.051516] [Citation(s) in RCA: 90] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
In rodent ovaries Kit ligand (KITL) and its receptor KIT have diverse roles, including the promotion of primordial follicle activation, oocyte growth, and follicle survival. Studies were undertaken to determine whether KITL and KIT carry out similar activities in rabbits. KitlandKitmRNA and protein were localized to oocytes and granulosa cells, respectively, in the rabbit ovary. Ovarian cortical explants from juvenile rabbits and neonatal mouse ovaries were subsequently cultured with recombinant mouse KITL and/or KITL neutralizing antibody. Indices of follicle growth initiation were compared with controls and between treatment groups for each species. Recombinant mouse KITL had no stimulatory effect on primordial follicle recruitment in cultured rabbit ovarian explants. However, the mean diameter of oocytes from primordial, early primary, primary, and growing primary follicles increased significantly in recombinant mouse KITL-treated explants compared with untreated tissues. In contrast, recombinant mouse KITL promoted both primordial follicle activation and an increase in the diameter of oocytes from primordial and early primary follicles in the mouse, and these effects were inhibited by coculture with KITL-neutralizing antibody. Recombinant mouse KITL had no effect on follicle survival for either species. These data demonstrate that KITL promotes the growth of rabbit and mouse oocytes and stimulates primordial follicle activation in the mouse but not in the rabbit. We propose that the physiologic roles of KITL and KIT may differ between species, and this has important implications for the design of in vitro culture systems for folliculogenesis in mammals, including the human.
Collapse
Affiliation(s)
- Karla J Hutt
- Pest Animal Control Cooperative Research Centre, CSIRO Sustainable Ecosystems, Canberra, Australian Capital Territory 2615, Australia
| | | | | |
Collapse
|
34
|
Kamakura Y, Hasegawa M, Minamoto T, Yamashita J, Fujisawa H. C-kit gene mutation: common and widely distributed in intracranial germinomas. J Neurosurg 2006; 104:173-80. [PMID: 16572634 DOI: 10.3171/ped.2006.104.3.173] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
OBJECT Of the intracranial germ cell tumors (IGCTs), 10% of germinomas and most nongerminomatous tumors remain refractory to multimodality therapy. The authors investigated the mutation of c-kit and the expression of its product KIT in IGCTs to identify tumors susceptible to imatinib mesylate, a synthetic agent targeting KIT. METHODS The authors investigated 26 IGCTs, including 13 germinomas, five mixed germ cell tumors (MGCTs), four immature teratomas (ITs), and two each of yolk sac tumors and choriocarcinomas. These tumors were examined for the expression of KIT and CD34 by immunohistochemical analysis, and for mutations in exons 2, 8 to 11, 13, and 17 of c-kit. Strong KIT expression was found in the cell membrane of germinomas (100%) and germinomatous cells of MGCTs (80%), as well as in the cytoplasm of epithelial and smooth-muscle cells of ITs. The membranous expression of CD34 was found in the nongerminomatous tumor cells and the chondrocytes of MGCTs (60%), ITs (100%), and a choriocarcinoma (50%), but not in germinomas and germinomatous cells. A total of five missense mutations distributed in exons 2, 11, 13, and 17 of c-kit were detected in three (23%) of the 13 germinomas. The novel mutations E73K, T96M (both in exon 2), and A636V (in exon 13) were detected in a single tumor. The presence or type of c-kit mutation was not correlated with patient prognosis. CONCLUSIONS Immunohistochemical analysis of KIT expression is useful for the diagnosis of germinoma. This study may help in clarifying the pathogenesis of IGCTs and in identifying tumors susceptible to drugs targeting KIT.
Collapse
Affiliation(s)
- Yayoi Kamakura
- Department of Neurosurgery, Kanazawa University Hospital, Japan
| | | | | | | | | |
Collapse
|
35
|
Hutt KJ, McLaughlin EA, Holland MK. Kit ligand and c-Kit have diverse roles during mammalian oogenesis and folliculogenesis. ACTA ACUST UNITED AC 2006; 12:61-9. [PMID: 16481408 DOI: 10.1093/molehr/gal010] [Citation(s) in RCA: 135] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Paracrine signalling between the oocyte and its surrounding somatic cells is fundamental to the processes of oogenesis and folliculogenesis in mammals. The study of animal models has revealed that the interaction of granulosa cell-derived kit ligand (KL) with oocyte and theca cell-derived c-Kit is important for multiple aspects of oocyte and follicle development, including the establishment of primordial germ cells within the ovary, primordial follicle activation, oocyte survival and growth, granulosa cell proliferation, theca cell recruitment and the maintenance of meiotic arrest. Though little is known about the specific roles of KL and c-Kit during human oogenesis, the expression profiles for KL and c-Kit within the human ovary suggest that they are also functionally relevant to female fertility. This review details our current understanding of the roles of KL and c-Kit within the mammalian ovary, with a particular focus on the functional diversity of this receptor-ligand interaction at different stages of oocyte and follicle development.
Collapse
Affiliation(s)
- K J Hutt
- Kansas University Medical Centre, Kansas City, USA
| | | | | |
Collapse
|
36
|
Barbara G, Stanghellini V, De Giorgio R, Corinaldesi R. Functional gastrointestinal disorders and mast cells: implications for therapy. Neurogastroenterol Motil 2006; 18:6-17. [PMID: 16371078 DOI: 10.1111/j.1365-2982.2005.00685.x] [Citation(s) in RCA: 132] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
The pathophysiology of functional gastrointestinal disorders is poorly understood. Accepted common mechanisms include psychosocial factors, abnormal gastrointestinal motility and disturbed visceral sensory perception, but the underlying causes remain unclear. Mast cells (MCs) are immunocytes widely distributed throughout the gastrointestinal tract. Several stimuli (e.g. allergens, neuropeptides and stress) lead to MC activation with consequent mediator release (e.g. histamine, tryptase and prostanoids). The MC mediators interact with nerves supplying the gut leading to altered gut physiology and increased sensory perception. The intestinal mucosa of irritable bowel syndrome patients contains on average an increased number of MCs. These cells release an increased amount of mediators in close vicinity to mucosal innervation. The MC activation and their close proximity to nerve fibres is correlated with the severity of perceived abdominal painful sensations. These data provide a strong basis for considering MCs as important participants in visceral hypersensitivity and pain perception in irritable bowel syndrome. Inhibition of MC function may ameliorate irritable bowel symptoms. Novel drugs with an increased potential in the control of MC function (e.g., anti-IgE antibodies, the intracellular protein tyrosine kinase inhibitor Syk) and mediator release (e.g., second generation antihistamines, proteinase-activated receptor antagonists) may be useful pharmacological tools for these common disorders.
Collapse
Affiliation(s)
- G Barbara
- Department of Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy.
| | | | | | | |
Collapse
|
37
|
Vakiani E, Cattoretti G, Colovai AI, Murty VV, Alobeid B, Bhagat G. CD117 expression in diffuse large B-cell lymphomas: fact or fiction? Pathol Int 2005; 55:716-23. [PMID: 16271084 DOI: 10.1111/j.1440-1827.2005.01893.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
CD117 (KIT) is expressed in a variety of hematopoietic neoplasms but there are a paucity of data regarding its expression in diffuse large B-cell lymphomas (DLBCL). The purpose of the present paper was to describe the authors' experience of two CD117+ DLBCL (one of follicle center-cell origin and one nasal Epstein-Barr virus (EBV)- plasmablastic lymphoma associated with lytic bone lesions), as determined by tissue immunohistochemistry and flow cytometry. The CD117 expression in DLBCL was further evaluated using tissue microarrays and seven additional plasmablastic lymphomas, using two commercially available anti-CD117 antibodies (Ab-1, Oncogene and A4502, DakoCytomation). Membranous +/- cytoplasmic staining was seen with Ab-1 in 24/65 (37%) DLBCL, including 21/56 microarray DLBCL, two index cases, and 1/7 additional plasmablastic lymphomas, with persistent staining in 13% of microarray DLBCL despite preincubation with KIT peptide. However, A4502 had only membranous staining of the index cases and one additional EBV- plasmablastic lymphoma with medullary disease. The present study suggests that (i) CD117 expression can be detected sporadically in DLBCL of follicle center-cell origin and a subset of plasmablastic lymphomas; (ii) staining for CD117 might help in identifying EBV- plasmablastic lymphomas associated with bone marrow involvement; and (iii) CD117 antibodies should be carefully validated prior to use, because non-specific staining, as observed with Ab-1, could lead to false-positive results.
Collapse
MESH Headings
- Bone Neoplasms/chemistry
- Bone Neoplasms/immunology
- Bone Neoplasms/pathology
- Female
- Hodgkin Disease/immunology
- Hodgkin Disease/metabolism
- Hodgkin Disease/pathology
- Humans
- Immunohistochemistry
- Leukemia, Lymphocytic, Chronic, B-Cell/chemistry
- Leukemia, Lymphocytic, Chronic, B-Cell/immunology
- Leukemia, Lymphocytic, Chronic, B-Cell/pathology
- Lymphoma, B-Cell/chemistry
- Lymphoma, B-Cell/immunology
- Lymphoma, B-Cell/pathology
- Lymphoma, Follicular/chemistry
- Lymphoma, Follicular/immunology
- Lymphoma, Follicular/pathology
- Lymphoma, Large B-Cell, Diffuse/chemistry
- Lymphoma, Large B-Cell, Diffuse/immunology
- Lymphoma, Large B-Cell, Diffuse/pathology
- Lymphoma, Mantle-Cell/chemistry
- Lymphoma, Mantle-Cell/immunology
- Lymphoma, Mantle-Cell/pathology
- Male
- Middle Aged
- Mouth Neoplasms/chemistry
- Mouth Neoplasms/immunology
- Mouth Neoplasms/pathology
- Proto-Oncogene Proteins c-kit/analysis
- Proto-Oncogene Proteins c-kit/immunology
- Skin Neoplasms/chemistry
- Skin Neoplasms/immunology
- Skin Neoplasms/pathology
- Soft Tissue Neoplasms/chemistry
- Soft Tissue Neoplasms/immunology
- Soft Tissue Neoplasms/pathology
- Splenic Neoplasms/chemistry
- Splenic Neoplasms/immunology
- Splenic Neoplasms/pathology
- Stomach Neoplasms/chemistry
- Stomach Neoplasms/immunology
- Stomach Neoplasms/pathology
Collapse
Affiliation(s)
- Efsevia Vakiani
- Department of Pathology, Columbia University, New York, NY, USA
| | | | | | | | | | | |
Collapse
|
38
|
Hagger R, Finlayson C, Jeffrey I, Kumar D. Role of the interstitial cells of Cajal in the control of gut motility. Br J Surg 2005. [DOI: 10.1046/j.1365-2168.1997.02736.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
39
|
Abstract
The development of the intestinal immune system is a complex sequence of events that begins in utero under various genetic influences, but continues after birth, being modified by factors such as bacteria, hormones and feeds. This review discusses what is known about the ontogeny of each aspect of the mucosal immune system so as to provide a better understanding of how aberrations in the system might lead to systemic disease.
Collapse
Affiliation(s)
- Jonathan E Teitelbaum
- Drexel University School of Medicine, Department of Pediatric Gastroenterology and Nutrition, Monmouth Medical Center, Long Branch, New Jersey, USA
| | | |
Collapse
|
40
|
Reddy P, Shen L, Ren C, Boman K, Lundin E, Ottander U, Lindgren P, Liu YX, Sun QY, Liu K. Activation of Akt (PKB) and suppression of FKHRL1 in mouse and rat oocytes by stem cell factor during follicular activation and development. Dev Biol 2005; 281:160-70. [PMID: 15893970 DOI: 10.1016/j.ydbio.2005.02.013] [Citation(s) in RCA: 115] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2004] [Revised: 02/10/2005] [Accepted: 02/10/2005] [Indexed: 11/24/2022]
Abstract
Although communications between mammalian oocytes and their surrounding granulosa cells mediated by the Kit-Kit ligand (KL, or stem cell factor, SCF) system have been proven to be crucial for follicular development, Kit downstream signaling pathways in mammalian oocytes are largely unknown. In this study, by using ovaries and isolated oocytes from postnatal mice and rats, we demonstrated for the first time that components of the PI3 kinase pathway, the serine/threonine kinase Akt (PKB) which enhances cellular proliferation and survival, and an Akt substrate FKHRL1 which is a transcription factor that leads to apoptosis and cell cycle arrest, are expressed in mammalian oocytes. By using an in vitro oocytes culture system, we found that oocytes-derived Akt and FKHRL1 are regulated by SCF. Treatment of cultured oocytes with SCF cannot only rapidly phosphorylate and activate Akt, but also simultaneously phosphorylate and may therefore functionally suppress FKHRL1, through the action of PI3 kinase. Together with our in situ hybridization and immunohistochemistry data that Akt and FKHRL1 are mostly expressed in oocytes in primordial and primary ovaries and reports that FKHRL1 gene-deficient mice exhibited excessive activation from primordial to primary follicles as well as enlarged oocyte sizes, we suppose that in mammalian oocytes, actions of granulosa cell derived SCF on primordial to primary follicle transition and subsequent follicle development may involve activation of Akt and inhibition of FKHRL1 activities in oocytes. The role of oocyte's Akt may be to enhance follicle development and the role of oocyte's FKHRL1 may be to inhibit follicle development. We propose that the cascade from granulosa cell SCF to oocyte Kit-PI3 kinase-Akt-FKHRL1 may play an important role to regulate the growth rate of mammalian oocytes and hypothetically also the oocyte secretion of factors that may regulate the activation and early development of ovarian follicles.
Collapse
Affiliation(s)
- Pradeep Reddy
- Department of Medical Biochemistry and Biophysics, Umeå University, S-901 87, Umeå, Sweden
| | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Stoop H, Honecker F, Cools M, de Krijger R, Bokemeyer C, Looijenga LHJ. Differentiation and development of human female germ cells during prenatal gonadogenesis: an immunohistochemical study. Hum Reprod 2005; 20:1466-76. [PMID: 15734757 DOI: 10.1093/humrep/deh800] [Citation(s) in RCA: 105] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND In the development of the human ovary, the second trimester includes the transition from oogonial replication to primordial follicle formation. The present study was carried out to assess differentiation and proliferation of germ cells in a series of female gonads from 19 fetuses from the second and third trimester, and two neonates. METHODS Using immunohistochemistry, the following markers were studied: placental/germ-like cell alkaline phosphatases (PLAP), the marker of pluripotency OCT3/4, the proliferation marker Ki-67, beta-catenin and E-cadherin, the stem cell factor receptor c-KIT, and VASA, a protein specific for the germ cell lineage. RESULTS PLAP and OCT3/4 were seen during oogenesis, but not in germ cells engaged in folliculogenesis. A similar pattern was observed for Ki-67. Loss of pluripotency occurs once oocytes engage in follicle formation, suggesting a role of cell-cell interactions in the process of germ cell maturation. VASA, c-KIT, beta-catenin and E-cadherin were found in germ cells at all developmental stages of oogenesis and folliculogenesis. CONCLUSIONS Immunohistochemically, two groups of germ cells can be distinguished. Germ cells that are predominantly found in the cortical region of the ovary before weeks 22-24 of gestation, showing an immature phenotype, are mitotically active, and express OCT3/4, a marker of pluripotency. On the other hand, germ cells undergoing folliculogenesis have lost their pluripotent potential and no longer proliferate.
Collapse
Affiliation(s)
- H Stoop
- Department of Pathology, Josephine Nefkens Institute, Erasmus MC-University Medical Center Rotterdam, Rotterdam, The Netherlands
| | | | | | | | | | | |
Collapse
|
42
|
Uzan C, Cortez A, Dufournet C, Fauvet R, Siffroi JP, Daraï E. Endometrium from women with and without endometriosis, and peritoneal, ovarian and bowel endometriosis, show different c-kit protein expression. J Reprod Immunol 2005; 65:55-63. [PMID: 15694967 DOI: 10.1016/j.jri.2004.09.002] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2004] [Revised: 09/10/2004] [Accepted: 09/14/2004] [Indexed: 11/16/2022]
Abstract
BACKGROUND Endometriosis is defined by the presence of endometrium outside the uterus. Changes in the expression of the proto-oncogene c-kit are associated with aggressive behaviour of both benign and malignant tumours, but there are few data on its c-kit expression in endometriosis. Here we examined c-kit expression in endometrium and endometriotic tissue. METHODS Immunohistochemistry was used for qualitative and semi-quantitative (mean+/-S.D. positive cells) analysis of c-kit expression in endometrium from women with (n=9) and without endometriosis (n=18), and in peritoneal (n=20), ovarian (n=20) and colorectal endometriosis (n=20). RESULTS Semi-quantitative c-kit expression was higher in endometrial glandular cells from women with endometriosis than from women without endometriosis (15.0+/-14.6% versus 3.9+/-7.4%, p=0.01). No difference in c-kit expression was found in qualitative analysis and according to the phase of the menstrual cycle. C-kit expression values in peritoneal, ovarian and colorectal endometriosis were 2.0+/-3.8%, 2.0+/-4.1% and 21.7+/-18.4%, respectively. Qualitative and semi-quantitative c-kit expression was higher in colorectal endometriosis than in peritoneal and ovarian endometriosis (p<0.001); no difference was found between ovarian and peritoneal endometriosis. No c-kit expression was detected in stromal cells of either endometrium or endometriotic tissue. CONCLUSION These results suggest that the c-kit/stem cell factor axis is involved in the pathogenesis of endometriosis. Strong c-kit protein expression was associated with invasive endometriotic lesions.
Collapse
Affiliation(s)
- Catherine Uzan
- Service d'Anatomie Pathologie, Hôpital Tenon, AP-HP, 4 rue de la Chine, 75020 Paris, France
| | | | | | | | | | | |
Collapse
|
43
|
Torihashi S, Yokoi K, Nagaya H, Aoki K, Fujimoto T. New monoclonal antibody (AIC) identifies interstitial cells of Cajal in the musculature of the mouse gastrointestinal tract. Auton Neurosci 2004; 113:16-23. [PMID: 15296791 DOI: 10.1016/j.autneu.2004.05.004] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2004] [Indexed: 11/26/2022]
Abstract
Interstitial cells of Cajal (ICC) are pacemaker cells for the spontaneous muscular contractions and neuromodulators that mediate neurotransmission from enteric neurons to smooth muscle cells in the gastrointestinal (GI) tract. They express c-Kit, and the antibody for c-Kit (especially ACK2) has been a useful tool for functional and morphological studies. ACK2, however, does not work on tissues fixed with paraformaldehyde, and not all ICC express c-Kit in human. Therefore, in order to find a new marker of ICC and/or new antibody resisting aldehyde fixation, we produced a new monoclonal antibody that identifies ICC and then investigated the properties of its antigen. Isolated ICC were used for immunization. Hybridomas fused with myeloma SP2 were screened by immunohistochemistry. ACK2 and each antibody were applied on serial sections, and the clone producing anti-ICC antibody (AIC) that stains ICC was established. The distribution of AIC immunopositive cells was examined in other organs and also GI muscles of W/Wv mice. The biochemical properties were studied using dot blot analysis. AIC recognized ICC; however, distribution of immunopositive cells in W/Wv mice and other organs was different from that of c-Kit. The immunoreactivity was stable for paraformaldehyde but was blocked by either Triton X-100 or SDS. In conclusion, new antibody AIC recognized ICC but the antigen was not c-Kit, which confirms the existence of good markers of ICC besides c-Kit. Although the antigen has not been isolated, AIC is suitable for morphological study and is useful for investigation of ICC in c-Kit mutants.
Collapse
Affiliation(s)
- S Torihashi
- Department of Anatomy and Molecular Cell Biology, Nagoya University Graduate School of Medicine, 65 Tsurumai, Showa Nagoya, 466-8550 Japan.
| | | | | | | | | |
Collapse
|
44
|
Abir R, Fisch B, Jin S, Barnnet M, Kessler-Icekson G, Ao A. Expression of stem cell factor and its receptor in human fetal and adult ovaries. Fertil Steril 2004; 82 Suppl 3:1235-43. [PMID: 15474101 DOI: 10.1016/j.fertnstert.2004.02.146] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2003] [Revised: 02/19/2004] [Accepted: 02/19/2004] [Indexed: 11/19/2022]
Abstract
OBJECTIVE To investigate the immunocytochemical expression and presence of mRNA transcripts of stem cell factor (SCF) and its receptor (SCF-R) in ovaries from human adults and fetuses. DESIGN Immunocytochemical and reverse transcription polymerase chain reaction (RT-PCR) study. SETTING Major tertiary care and referral academic centers. PATIENT(S) Seven women and girls undergoing laparoscopic ovarian biopsy and 13 women undergoing second and third trimester pregnancy terminations. INTERVENTION(S) None. MAIN OUTCOME MEASURE(S) Microscopic morphometric analysis, immunocytochemistry for SCF and SCF-R, and RT-PCR analyses. RESULT(S) There was strong to moderate immunocytochemical staining for SCF and its receptor in oocytes from primordial stages onward, but not in granulosa cells, in both fetal and adult ovarian samples. Transcripts of SCF and SCF-R RNA were detected by RT-PCR analyses for SCF and SCF-R. CONCLUSION(S) The expression of SCF and its receptor in ovarian tissue from fetuses and women suggests a possible role of SCF in growth initiation of human primordial follicles.
Collapse
Affiliation(s)
- Ronit Abir
- Department of Obstetrics and Gynecology, Rabin Medical Center, Beilinson Campus, Petah Tikva Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
| | | | | | | | | | | |
Collapse
|
45
|
Kang JS, Lee CJ, Lee JM, Rha JY, Song KW, Park MH. Follicular expression of c-Kit/SCF and inhibin-alpha in mouse ovary during development. J Histochem Cytochem 2003; 51:1447-58. [PMID: 14566017 PMCID: PMC3957554 DOI: 10.1177/002215540305101105] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
The mechanism of development of the ovarian follicles has been largely unknown. We performed an immunohistochemical (IHC) study to determine the follicular expressions of c-kit, SCF, and inhibin-alpha at different developmental stages in mouse ovary. Ovaries were obtained from 14 and 16 days post coitum and 2, 7, and 21 days post partum (dpp) mice. IHC for c-kit, SCF, and inhibin-alpha was carried out. c-Kit and SCF were expressed on oogonia regardless of the developmental stage. Immunoreactive c-kit and SCF antigens were expressed on oocytes of primordial and primary follicles of neonate mouse ovaries. In 21 dpp mouse ovary, the expression of c-kit/SCF in oocytes gradually decreased as the follicles developed. c-Kit/SCF was expressed strongly in oocytes of preantral follicles and weakly in granulosa and thecal cells. Inhibin-alpha was mainly expressed on granulosa cells of preantral and early antral follicles of the 21 dpp mouse ovaries. These findings suggest that the IHC expression of c-kit/SCF proteins is specific in all developmental stages of ovarian follicles and is decreased after the follicle starts to grow. The expression of inhibin-alpha is negatively correlated with the expression of c-kit/SCF in the ovarian follicles in mice.
Collapse
Affiliation(s)
- Jae Seong Kang
- Department of Obstetrics and Gynecology, Korea University Hospital (JSK,CJL,JYR), Seoul, Korea
| | - Chang Joo Lee
- Department of Obstetrics and Gynecology, Korea University Hospital (JSK,CJL,JYR), Seoul, Korea
| | - Jong Min Lee
- Department of Obstetrics and Gynecology, Gachon Medical School (JML), Seoul, Korea
| | - Joong Yeol Rha
- Department of Obstetrics and Gynecology, Korea University Hospital (JSK,CJL,JYR), Seoul, Korea
| | - Kang Won Song
- Department of Pathology, College of Medicine, Hanyang University, (KWS,MHP), Seoul, Korea
| | - Moon Hyang Park
- Department of Pathology, College of Medicine, Hanyang University, (KWS,MHP), Seoul, Korea
- Correspondence to: Moon Hyang Park, Dept. of Pathology, College of Medicine, Hanyang University, 17, Haengdang-dong, Seongdong-gu, Seoul, Republic of Korea. E-mail:
| |
Collapse
|
46
|
Winter WE, Seidman JD, Krivak TC, Chauhan S, Carlson JW, Rose GS, Birrer MJ. Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of the uterine corpus. Gynecol Oncol 2003; 91:3-8. [PMID: 14529656 DOI: 10.1016/j.ygyno.2003.06.001] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
OBJECTIVE The purpose of this study was to evaluate the expression of the protooncogene, c-kit, in carcinosarcomas and leiomyosarcomas of the uterine corpus and determine the associations between c-kit expression and clinicopathologic factors, including clinical outcome. METHODS AND MATERIALS Using a polyclonal anti-KIT-antibody, immunohistochemical staining was performed on formalin-fixed paraffin-embedded tissue blocks from 21 carcinosarcomas, 17 leiomyosarcomas, and 1 endometrial stromal sarcoma. KIT-positive tumors were defined as those tumors demonstrating immunopositivity in > or =30% of tumor cells examined. KIT-negative lesions demonstrated immunopositivity in <30% of tumor cells. Two authors independently scored the slides as positive or negative. Staining was repeated on all specimens and independently scored, and in the occasion of a mismatch, a third staining was performed. The carcinosarcomas were catalogued as to whether the sarcomatous and/or carcinomatous elements expressed c-kit. Clinical data were abstracted for those patients with uterine carcinosarcomas. The associations between clinicopathologic characteristics and c-kit expression were compared using univariate and multivariate analyses. Kaplan-Meier curves based on c-kit expression were plotted for progression-free and overall survival and compared using the log-rank test. RESULTS Nine of 21 (43%) carcinosarcomas demonstrated immunopositivity for the KIT receptor, although staining was relatively weak. In contrast, only 1/17 (6%) leiomyosarcomas demonstrated KIT immunopositivity (P = 0.029). The solitary endometrial stromal sarcoma evaluated did not demonstrate significant KIT positivity. The majority of KIT-positive carcinosarcomas (6/9 (67%)) demonstrated KIT presence in the sarcomatous portion as compared to the carcinomatous portion (4/9 (44%)). No clinical factor had a statistically significant association with c-kit expression. The lack of c-kit expression was the only factor that was significantly associated with disease recurrence in univariate and multivariate analyses (P < 0.05), although there appeared to be a trend toward a low stage associated with kit positivity. The median progression-free interval for the KIT-negative cohort was 8 months, while it had not been reached for the KIT-positive cohort after median follow-up of 15 months (P = 0.0462). CONCLUSIONS A significant proportion of carcinosarcomas of the uterine corpus display immunoreactivity for c-kit. Patients with KIT-positive carcinosarcomas may have an improved progression-free survival compared to KIT-negative tumors; however, further data are needed to determine whether this finding is confounded by stage.
Collapse
Affiliation(s)
- William E Winter
- Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Walter Reed Army Medical Center, Washington, DC 20307, USA
| | | | | | | | | | | | | |
Collapse
|
47
|
Wang L, Felix JC, Lee JL, Tan PY, Tourgeman DE, O'Meara AT, Amezcua CA. The proto-oncogene c-kit is expressed in leiomyosarcomas of the uterus. Gynecol Oncol 2003; 90:402-6. [PMID: 12893208 DOI: 10.1016/s0090-8258(03)00274-9] [Citation(s) in RCA: 65] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
OBJECTIVE The proto-oncogene c-kit encodes for a 145-kDa transmembrane tyrosine kinase receptor. Interaction with its ligand, stem cell factor, is essential in the development of hematopoietic stem cells, mast cells, gametocytes, melanocytes, and interstitial cells of Cajal. C-kit expression has been identified in a number of different neoplasms that includes mastocytosis/mast cell leukemia, acute myeloblastic leukemia, seminoma/dysgerminoma, and gastrointestinal stromal tumors. This study examines c-kit expression in uterine endometrial stromal sarcomas, leiomyomas, and leiomyosarcomas using immunohistochemistry. METHODS Archival tissue from 38 patients with the uterine mesenchymal tumors (16 leiomyosarcomas, 8 leiomyomas, 11 low-grade endometrial stromal sarcomas, and 3 high-grade endometrial stromal sarcomas) was stained with polyclonal antibody for c-kit. Modified avidin biotin (ABC) immunoperoxidase method was employed for antibody detection. Individual tumors were considered positive if more than 10% of the cells comprising the neoplasm displayed immunoreactive staining. Staining intensity was graded 1+ to 3+ and distribution graded as focal (10-30% of the cells), intermediate (30-60% of the cells), or diffuse (>60% of the cells). RESULTS C-kit was positive in 12 (75%) of the 16 leiomyosarcomas. The staining was 3+ and diffuse in the majority of the positive tumors. C-kit expression was not detected in any of the 8 leiomyomas. Two of the 3 high-grade endometrial stromal sarcomas displayed c-kit positivity. Staining was diffuse and 3+ in both of these tumors. Expression of c-kit was observed in only 3 of the 11 low-grade endometrial stromal sarcomas. CONCLUSIONS C-kit is expressed in uterine leiomyosarcomas and endometrial stromal sarcomas. Adjunctive diagnostic studies using c-kit may be useful in distinguishing leiomyosarcomas from benign leiomyomas in uterine tumors that offer uncharacteristic features. Furthermore, studies should investigate the prospect of treating these malignant tumors with tyrosine kinase inhibitors.
Collapse
Affiliation(s)
- Lina Wang
- Department of Pathology, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
| | | | | | | | | | | | | |
Collapse
|
48
|
Scobie JV, Acs G, Bandera CA, Blank SV, Wheeler JE, Pasha TL, Salscheider M, Zhang PJ. C-kit immunoreactivity in endometrial adenocarcinomas and its clinicopathologic significance. Int J Gynecol Pathol 2003; 22:149-55. [PMID: 12649669 DOI: 10.1097/00004347-200304000-00006] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
The proto-oncogene c-kit is a transmembrane-tyrosine-kinase receptor that is structurally related to the platelet-derived growth-factor receptor (PDGFR) and is involved in cell differentiation. C-kit has been found to be expressed in certain solid tumors and may play a role in their tumorigenesis. Recently, a tyrosine-kinase inhibitor specific for the PDGFR family, bcr-abl, and c-kit (STI571) has been reported to have therapeutic effects in tumors expressing the aberrant forms or high quantities of target proteins. Expression of c-kit has not been well evaluated in endometrial adenocarcinomas. In this study, c-kit immunoreactivity was evaluated on paraffin sections of 72 endometrial adenocarcinomas (57 endometrioid, 10 serous, and 5 clear cell) with a polyclonal antibody. Immunoreactivity of c-kit was analyzed semiquantitatively and correlated with various clinicopathologic factors. Cytoplasmic c-kit immunoreactivity was detected in 42 (58%) tumors. Thirty-four (60%) endometrioid, 8 (80%) serous, and 0 of the 5 clear-cell adenocarcinomas were c-kit positive. There was a significant correlation between c-kit positivity and the depth of myometrial invasion. Patients with c-kit-positive endometrial adenocarcinomas more frequently had metastases and shorter disease-free survival. Expression of c-kit may be a potentially adverse prognostic feature in endometrial adenocarcinoma. Patients with c-kit-positive advanced endometrial adenocarcinoma might benefit from tyrosine-kinase-inhibitor therapy.
Collapse
Affiliation(s)
- Janice V Scobie
- Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, USA
| | | | | | | | | | | | | | | |
Collapse
|
49
|
Porcher C, Baldo M, Henry M, Orsoni P, Julé Y, Ward SM. Deficiency of interstitial cells of Cajal in the small intestine of patients with Crohn's disease. Am J Gastroenterol 2002; 97:118-25. [PMID: 11808934 DOI: 10.1111/j.1572-0241.2002.05430.x] [Citation(s) in RCA: 79] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
OBJECTIVE Interstitial cells of Cajal are critical for the generation of electrical slow waves that regulate the phasic contractile activity of the tunica muscularis of the GI tract. Under certain pathophysiological conditions loss of interstitial cells of Cajal may play a role in the generation of certain motility disorders. The aim of the present study was to determine if there is an abnormality in the density or distribution of interstitial cells of Cajal from patients with Crohn's disease. METHODS Small intestines from control subjects and patients with Crohn's disease were examined using immunohistochemistry and antibodies against the Kit receptor, which is expressed in interstitial cells of Cajal within the tunica muscularis of the GI tract. The density and distribution of interstitial cells of Cajal were assessed in the longitudinal and circular muscle layers and in the myenteric and deep muscular plexus regions of Crohn's and control tissues. RESULTS Tissues from Crohn's disease patients showed an almost complete abolition of interstitial cells of Cajal within the longitudinal and circular muscle layers and a significant reduction in numbers at the level of the myenteric and deep muscular plexuses. CONCLUSIONS In tissues from Crohn's disease patients, the density of interstitial cells of Cajal was reduced throughout the tunica muscularis in comparison to control small intestines. The disturbance of intestinal motility that occurs in patients with Crohn's disease may be a consequence of the loss of or defects in specific populations of interstitial cells of Cajal within the tunica muscularis.
Collapse
Affiliation(s)
- Christophe Porcher
- Department of Physiology and Neurophysiology, CNRS-ESA 6034, Faculé des Sciences de Saint-Jérĵme, Marseille, France
| | | | | | | | | | | |
Collapse
|
50
|
Ito M, Harada T, Tanikawa M, Fujii A, Shiota G, Terakawa N. Hepatocyte growth factor and stem cell factor involvement in paracrine interplays of theca and granulosa cells in the human ovary. Fertil Steril 2001; 75:973-9. [PMID: 11334911 DOI: 10.1016/s0015-0282(01)01747-2] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
OBJECTIVE To examine gene expression of hepatocyte growth factor (HGF), the receptor for HGF, c-met, and the receptor for stem cell factor (SCF), c-kit, in the human ovary and to investigate the effects of HGF and SCF on the proliferation and function of granulosa and theca cells. DESIGN Prospective study. SETTING University hospital. PATIENT(S) Six premenopausal women. INTERVENTION(S) Follicular fluid and granulosa cells were collected during IVF cycles. Ovarian tissues were obtained from women who underwent surgery. MAIN OUTCOME MEASURE(S) Gene expression of HGF, c-met, and c-kit in the human ovary was determined. RESULT(S) Reverse-transcription polymerase chain reaction showed the presence of HGF and c-kit mRNA in the theca and stroma cells of the ovary, whereas c-met mRNA was observed in the granulosa, theca, and stroma cells. HGF increased the expression of SCF gene in granulosa cells, and SCF reciprocally increased the expression of HGF gene in theca cells. SCF stimulated the proliferation of theca cells. HGF stimulated progesterone production in granulosa cells. CONCLUSION(S) A positive feedback loop between theca cells and granulosa cells was identified that is mediated by HGF and SCF. HGF and SCF modulate the interplay between theca and granulosa cells by promoting cell proliferation and steroid hormone production.
Collapse
Affiliation(s)
- M Ito
- Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago, Japan
| | | | | | | | | | | |
Collapse
|